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The β2 adrenergic receptor (β2AR) regulates smooth muscle relaxation in the
vasculature and airways. Long- and Short-acting β-agonists (LABAs/SABAs) are
widely used in treatment of chronic obstructive pulmonary disorder (COPD) and
asthma. Despite their widespread clinical use we do not understand well the dominant
β2AR regulatory pathways that are stimulated during therapy and bring about
tachyphylaxis, which is the loss of drug effects. Thus, an understanding of how the
β2AR responds to various β-agonists is crucial to their rational use. Towards that end
we have developed deterministic models that explore the mechanism of drug- induced
β2AR regulation. These mathematical models can be classified into three classes; (i)
Six quantitative models of SABA-induced G protein coupled receptor kinase (GRK)mediated β2AR regulation; (ii) Three phenomenological models of salmeterol (a
LABA)-induced GRK-mediated β2AR regulation; and (iii) One semi-quantitative,
unified model of SABA-induced GRK-, protein kinase A (PKA)-, and
phosphodiesterase (PDE)-mediated regulation of β2AR signalling. The various models
were constrained with all or some of the following experimental data; (i) GRK-mediated
β2AR phosphorylation in response to various LABAs/SABAs; (ii) dephosphorylation of
the GRK site on the β2AR; (iii) β2AR internalisation; (iv) β2AR recycling; (v) β2AR
desensitisation; (vi) β2AR resensitisation; (vii) PKA-mediated β2AR phosphorylation in
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response to a SABA; and (viii) LABA/SABA induced cAMP profile ± PDE inhibitors.
The models of GRK-mediated β2AR regulation show that plasma membrane
dephosphorylation and recycling of the phosphorylated β2AR are required to reconcile
with the measured dephosphorylation kinetics. We further used a consensus model to
predict the consequences of rapid pulsatile agonist stimulation and found that although
resensitisation was rapid, the β2AR system retained the memory of prior stimuli and
desensitised much more rapidly and strongly in response to subsequent stimuli. This
could explain tachyphylaxis of SABAs over repeated use in rescue therapy of asthma
patients. The LABA models show that the long action of salmeterol can be explained
due to decreased stability of the arrestin/β2AR/salmeterol complex. This could explain
long action of β-agonists used in maintenance therapy of asthma patients. Our
consensus model of PKA/PDE/GRK-mediated β2AR regulation is being used to
identify the dominant β2AR desensitisation pathways under different therapeutic
regimens in human airway cells. In summary our models represent a significant
advance towards understanding agonist-specific β2AR regulation that will aid in a
more rational use of the β2AR agonists in the treatment of asthma.
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Introduction
1.1. GPCRs
The G protein-coupled, seven-transmembrane receptors (GPCRs or 7TM
receptors) are encoded by one of the largest gene families (Vroling, Sanders et al.
2011). They are targeted by > 25% FDA approved drugs (Flower 1999;
Overington, Al-Lazikani et al. 2006). Based on hydropathy profiles and the crystal
structure of bovine rhodopsin (Palczewski, Kumasaka et al. 2000) and human β2
adrenergic receptor (β2AR) (Cherezov, Rosenbaum et al. 2007; Rasmussen, Choi
et al. 2007; Rosenbaum, Cherezov et al. 2007) all GPCRs are thought to have the
same molecular architecture, consisting of seven trans-membrane domains, three
extra- and intra-cellular loops, an extracellular amino-terminal and an intracellular
carboxyl-terminal domain. GPCRs are named thus due to their action as guaninenucleotide exchange factors at the heterotrimeric G proteins (comprising of an α-,
β- and γ-subunit) leading to the exchange of GDP for GTP bound to the α-subunit
post GPCR activation (Gilman 1987; Johnston and Siderovski 2007). The GTPbound α-subunit and the released βγ-dimer of the G protein can stimulate or inhibit
effector molecules like adenylyl and guanylyl cyclases, phospholipases,
phosphodiesterases and phosphoinositide 3-kinases (PI3Ks) (Rall and Sutherland
1962; Sutherland, Rall et al. 1962; Jelsema and Axelrod 1987; Tang and Gilman
1991; Camps, Carozzi et al. 1992). This in turn activates or inhibits the production
of second messengers like cyclic adenosine monophosphate (cAMP), cyclic
guanosine monophosphate (cGMP), diacylglycerol (DAG), inositol trisphosphate
(IP3), phosphatidyl inositol trisphosphate (PIP3), arachidonic acid (AA) and
1

phosphatidic acid (PA), in addition to the opening or closing of a variety of ion
channels (Sutherland and Robison 1966; Hardman, Robison et al. 1971; Goldberg,
O'Dea et al. 1973; Lapetina and Michell 1973; Brindley and Waggoner 1996).
GPCRs can be classified into six families based on functional similarity and
sequence homology (Attwood and Findlay 1994; Kolakowski 1994; Bjarnadottir,
Gloriam et al. 2006). The similarity in 7TM topology across GPCR families is
believed to be due to evolutionary convergence (Bockaert and Pin 1999). GPCR
families have >20% amino acid sequence similarity within their trans-membrane
helices (Kolakowski 1994; Kristiansen 2004). β2AR belongs to the family of
Rhodospsin-like GPCRs. This Class A family is classified into 19 subgroups (A1A19) based on phylogenetic analysis of 241 sequences (Joost and Methner 2002),
and the β2AR which is a Gαs-coupled GPCR belongs to subfamily A17.
1.1.1. Adrenergic Receptor Classification
Adrenergic receptors are a Class A GPCR that are targetted by
catecholamines like norepinephrine and epinephrine. They can be classified
into two groups, α and β, with subtypes in each group. The α receptors are
either α1 or α3 where they are coupled to Gq and Gi respectively. All three
subtypes of β receptors – β1, β 2 and β3 are coupled to Gs and can activate
adenylyl cyclases leading to cAMP-mediated downstream signalling. The major
locale of β1AR is the cardiac muscle where it is involved in regulation of
cardiac output by increasing speed and force of contraction. The β2AR is near
ubiquitously expressed and regulates smooth muscle relaxation in uterus, GI
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tract, bronchi and blood vessels. The β3AR is predominantly found in adipose
tissue and regulates lipolysis and thermogenesis.
1.1.2. Role of β2AR in Smooth Muscle Relaxation
β2AR agonists increase cAMP levels in airway smooth muscle that is
consistent with their relaxation response (Katsuki and Murad 1977; Wong and
Buckner 1978; Rinard, Rubinfeld et al. 1979; Zhou, Newsholme et al. 1992).
Phosphodiesterases degrade cAMP and abrogate cAMP-mediated signalling.
Phosphodiesterase inhibitors (4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-5methyl-3(2H)-pyridazinone (CI-930), 3-isobutyl-1-methylxanthine (IBMX), 4-(3Butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro 20-1724), rolipram,
siguazodan, SK&F 94120 and zaprinast) mimic and increase the response to
β2AR agonists (Harris, Connell et al. 1989; Torphy, Zhou et al. 1991; Qian,
Naline et al. 1993; Torphy, Undem et al. 1993). cAMP analogues (8-(4chlorophenylthio)-cAMP, 8-bromo-cAMP, 8-(6-aminohexylamino)-cAMP, N6benzoyl-cAMP, N6-2’-O-dibutyryl-cAMP and N6-monobutyryl cAMP) mimic the
relaxation effect of β2AR agonists (Bresnahan, Borowitz et al. 1975; Napoli,
Gruetter et al. 1980; Heaslip, Giesa et al. 1987; Francis, Noblett et al. 1988).
β2AR agonists regulate cAMP-dependent protein kinase A (PKA) in airway
smooth muscle consistent with the relaxation response (Torphy, Freese et al.
1982; Giembycz and Diamond 1990; Zhou, Newsholme et al. 1992). Myosin
Light Chain Phosphatase (MLCP) can be activated by cyclic GMP/AMP
activated kinases (Janssen, Tazzeo et al. 2004). cAMP can also cross activate
cyclic GMP activated kinase (PKG) in smooth muscle (Francis, Noblett et al.
3

1988). PKA phosphorylation of the IP3 receptor inhibits binding of IP3 to the
receptor. This reduces release of calcium from internal pools in response to
bronchioconstrictors (Schramm, Chuang et al. 1995).
Bronchioconstrictors can activate kinases like ROCK which inactivate MYPT1
a subunit of MLCP. This inhibitory phosphorylation on MYPT1 can be blocked
by phosphorylation of MYPT1 by PKG/PKA (Wooldridge, MacDonald et al.
2004). MLCK can be activated by ERK1(Morrison, Sanghera et al. 1996).
MAPK Phosphatase 1 (MKP1) dephosphorylates and inactivates ERK1. MKP1
can be activated by agonist activation of β2AR (Brondello, Brunet et al. 1997;
Price, Chik et al. 2004). β2AR activation by agonists leads to membrane
hyperpolarisation through activation of big conductance Ca2+ activated K
channels (BKCa) in the plasma membrane counteracting electrical excitation
and subsequent Ca2+ influx. Iberiotoxin mediated inhibition of BKCa prevents
hyperpolarisation and β2AR mediated ASM relaxation (Jones, Charette et al.
1993). The α subunit of BKCa has been shown to interact with β2AR and
AKAP79 in ASM (Liu, Shi et al. 2004). PKA phosphorylation of the BKCa
channel subunits has an activating or inactivating effect based on the splice
isoform (Tian, Coghill et al. 2004). PKG also differentially activates various
splice isoforms of the BKCa channel (Zhou, Arntz et al. 2001). All this (Figure
1.1) provides compelling evidence that β2AR activation mediates smooth
muscle relaxation through both cAMP-dependent and -independent signalling.
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Figure 1.1 β2AR Agonist Induced ASM Relaxation/Contraction Pathways.
The arrows indicate a direct or indirect effect; green arrows indicate an activating effect and
the red arrows indicate an inhibitory effect.

5

In the light of the role of β2AR in ASM relaxation, β2AR agonists are used in
the palliative treatment of inflammatorydiseases of the airways such as chronic
obstructive pulmonary disease (COPD) and asthma (Connors, Dawson et al.
1996; Celli and MacNee 2004; Donohue 2004). These include short-acting
(SABA) and long-acting (LABA) β-agonists. SABAs are generally used as
required for immediate relief in the treatment of acute asthma while LABAs are
recommended for longer term use in combination with an inhaled steroid. βagonists have both bronchodilatory and bronchoprotective effects.
Bronchodilation is the effect of lung inflation post airway smooth muscle
relaxation. Bronchoprotection is the resistance to contraction on inhalation of a
bronchioconstrictor like methacholine which acts on muscarinic receptors.
Excessive and prolonged use of β2AR agonists leads to tachyphylaxis – which
is the loss of both broncholdilatory and bronchoprotective effects of the drug
(Keighley 1966; Van Metre 1969; Davis and Conolly 1980; Sears 2002;
Abramson, Walters et al. 2003). It has been noted that repeated aerosolised
administration of a β2AR agonist like salbutamol or isoproterenol leads to a
decrease in spirometric measures like the forced vital capacity (FVC) and
forced expiratory volume in 1 second (FEV1)in asthmatic patients within 180
min (isoproterenol) and beyond 300 min (salbutamol) (Choo-Kang, Simpson et
al. 1969). There is an increased rebound in bronchoconstriction in asthmatics
following a prolonged isoproterenol treatment (Paterson, Evans et al. 1971)
where rebound is defined as a fall in mean peak flow below baseline after
6

stopping treatment with β-agonists. Even healthy individuals show reduced
bronchodilatory effects (as measured by specific airway conductance) over a 4
week long exposure to a β-agonist like salbutamol (Holgate, Baldwin et al.
1977). The tachyphylaxis to β-agonists has been attributed to desensitisation
of the β2AR (Davis and Conolly 1980; Bruynzeel 1984; Bruynzeel, Meurs et al.
1985). Thus understanding β2AR desensitisation mechanisms would help in
rationale design of drug combinations that would allow for longer action of βagonists by inhibiting the agonist-specific dominant modes of β2AR
desensitisation.
1.1.3. β2AR Desensitisation
β2AR desensitisation occurs in response to agonist-induced activation of the
receptor. The major mechanisms by which desensitisation of β2AR signalling
can occur are: (1) Phosphorylation of the receptor (Benovic, Kuhn et al. 1987;
Kobilka, MacGregor et al. 1987; Bouvier, Hausdorff et al. 1988; Lohse,
Lefkowitz et al. 1989; Roth, Campbell et al. 1991; Yuan, Friedman et al. 1994;
Vaughan, Millman et al. 2006), (2) internalisation of uncoupled β2AR (Sher and
Clementi 1985; Yu, Lefkowitz et al. 1993; Barak, Tiberi et al. 1994; Ferguson,
Downey et al. 1996; January, Seibold et al. 1997; Conway, Minor et al. 1999;
Seibold, Williams et al. 2000; Clark and Knoll 2002), and (3)
phosphodiesterase activation and subsequent degradation of cAMP (Barber,
Goka et al. 1992; Broadley 1999). The extent of activation of individual
modules of desensitisation is dependent on the amount, duration, type of βagonist and amount of β2AR (Whaley, Yuan et al. 1994; Tran, Friedman et al.
7

2004). Figure 1.2 describes these overall reaction modules in β2AR
desensitisation.

8

Figure 1.2 Modules of β2AR Regulation.
The reactions involved in β2AR regulation are classified into G-protein independent and
dependent pathways. The ‘+’ signs indicate a stimulatory effect of the modules along the
direction of the arrow and a ‘-‘ sign indicates an inhibitory effect.

9

1.1.3.1.

β2AR Phosphorylation

Kinase-mediated phosphorylation of the βAR is a major mode of receptor
desensitisation (Stadel, Nambi et al. 1983; Hertel and Perkins 1984; Sibley,
Benovic et al. 1987; Clark, Kunkel et al. 1988; Krupnick and Benovic 1998).
At low concentrations of hormones or β-agonists there is a high potency,
cAMP-dependent protein kinase A mediated, heterologous desensitisation
of β2AR signalling (Benovic, Pike et al. 1985; Clark, Friedman et al. 1987;
Clark, Kunkel et al. 1988; Lohse, Benovic et al. 1990; Tran, Friedman et al.
2004). In concurrence with this it was shown that mutation of putative PKA
phosphorylation sites on β2AR led to marked reduction of desensitisation at
low agonist concentrations (Hausdorff, Bouvier et al. 1989; Yuan, Friedman
et al. 1994). Our group has shown that PKA activation leads to
phosphorylation of at least S262 (Seibold, Williams et al. 2000). Mass
spectrometric analysis (Trester-Zedlitz, Burlingame et al. 2005) of a small
peptide containing the S262 site showed a stoichiometry of phosphorylation
of one, which is in agreement with our results with PKA-mediated
phosphorylation. Desensitisation of the receptor is achieved by causing a
reduction in coupling efficiency of the receptor to Gs by from ~20% (GRK) to
~ 60% (PKA).
At high agonist concentrations there is a low potency, receptor occupancy
driven, G-protein receptor kinase (GRK) mediated receptor phosphorylation
(Benovic, Strasser et al. 1986; Clark, Kunkel et al. 1988; Palczewski 1997;
Tran, Friedman et al. 2004). GRK activation leads to the phosphorylation of
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at least three serine residues on the carboxyl tail of the receptor, viz. S355,
S356, and S364 (Seibold, Williams et al. 2000). Our group has further
characterised the S-355,356 sites by the use of phosphosite-specific
antibody directed against pS-355,356 (Tran, Friedman et al. 2004). Mass
spectrometric analysis of a peptide (residues 349-372) containing the three
GRK sites showed that it was phosphorylated in HEK293 cells (TresterZedlitz, Burlingame et al. 2005). Stoichiometric analysis indicated that
phosphorylation of S-355,356 was agonist-dependent, and S-364 was
constitutively phosphorylated. Through siRNA studies it has been shown
that GRK6 knockdown reduced S-355,356 phosphorylation by fivefold
whereas GRK2 depletion increased isoproterenol-induced phosphorylation
of these sites by 1.5 fold as detected by liquid chromatography–tandem
mass spectrometry (Nobles, Xiao et al. 2011). In the same studies it has
been suggested that GRK6-mediated phosphorylation of the β2AR is
important for β-arrestin–dependent ERK1/2 activation, whereas GRK2
phosphorylation of the receptor may inhibit β2AR signalling to ERK1/2 on
account of differences in reduction of ERK1/2 phosphorylation by either
isoproterenol or carvedilol.
The GRK-mediated desensitisation of β2AR-mediated AC activation
dominates only at higher agonist concentration due to the lack of significant
amplification steps as compared to the PKA-mediated desensitisation at
lower agonist concentrations. Our group has studied the effect of varying
levels of β2AR expression on activation of adenylyl cyclase through Gαs
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(Whaley, Yuan et al. 1994). We predicted the relationship between receptor
number and EC50 of adenylyl cyclase activation. As the receptor density
increased from 5 to 5000 fmol/mg of protein the EC50 for epinephrine
activation of adenylyl cyclase decreased from 200 to 0.2 nM (Whaley, Yuan
et al. 1994; Xin, Tran et al. 2008). The EC50s on treatment with isoproterenol
for the PKA and GRK site phosphorylations respectively are 30 pM and 200
nM in HEK 293 cells stably overexpressing the β2AR (Tran, Friedman et al.
2004). Thus there is a large separation of the two pathways in cells with high
β2AR levels as a function of agonist concentration. This large separation of
the EC50s is not expected in HASMs where the receptor number is much
lower and therefore the EC50s will approach the Kds.
1.1.3.2.

β2AR Internalisation

PKA or GRK phosphorylation of β2AR by itself is insufficient to produce
complete desensitisation (Lohse, Benovic et al. 1990). A cofactor called
arrestin is required to completely desensitise the β2AR post GRKphosphorylation (Lohse, Benovic et al. 1990) since it completely uncouples
the receptor from Gαs (Pan, Gurevich et al. 2003; Krasel, Bunemann et al.
2005). Arrestins bind directly to most GRK-phosphorylated GPCRs, forming
a stoichiometric complex that is precluded from further G protein coupling. A
polar core located in the hinge region between the two globular domains of
the arrestin interacts with both non-phosphorylated and GRKphosphorylated residues on the receptor tail (Hanson and Gurevich 2006).
Receptor binding produces significant conformational changes in the
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arrestin (Gurevich and Benovic 1993; Hirsch, Schubert et al. 1999;
Vishnivetskiy, Paz et al. 1999; Vishnivetskiy, Schubert et al. 2000;
Vishnivetskiy, Hirsch et al. 2002), whereas, conversely, arrestin binding
stabilizes a receptor state with high agonist affinity, prompting some authors
to characterise the receptor-arrestin complex as an alternative ternary
complex analogous to the ternary complex of agonist-receptor-G protein in
the absence of GTP (Gurevich, Pals-Rylaarsdam et al. 1997).
Both GRK phosphorylation and agonist-induced β2AR activation are a
prerequisite to arrestin binding the receptor (Krasel, Bunemann et al. 2005).
β-arrestin binding leads to the internalisation of the receptor via recruitment
of clathrin and protein AP-2 (Koenig and Edwardson 1997). The internalised
receptor either recycles back to the plasma membrane in a fully sensitised
state (Yu, Lefkowitz et al. 1993), is targetted to lysosomes for degradation
(Williams, Barber et al. 2000) or is a scaffold for signalling proteins like
MAPK (Pierce, Maudsley et al. 2000; Huang, Sun et al. 2004; Xu, Baillie et
al. 2008).
1.1.3.3.

Phosphodiesterase Activity

The PDE superfamily is grouped through functional and homology
classification into 11 subfamilies (Soderling and Beavo 2000). Inspite of
being encoded by just 21 genes close to 200 plus distinct PDEs are reported
on account of extensive alternative RNA splicing and multiple promoters
(Bingham, Sudarsanam et al. 2006). PDEs across families are functionally
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distinguished on account of distinct combination of pharmacological
inhibitory profiles and unique enzymatic charactersistics with individual
families showcasing distinct allosteric modifiers of enzyme activity. Individual
PDEs also have distinct distribution at the tissue, cellular and subcellular
level. The PDE4A-D subfamily is subject to considerable pharmacological
scrutiny on account of its role in various disease states like respiratory
disease (Conti, Richter et al. 2003; Houslay, Baillie et al. 2007). Increase in
cAMP levels is the major stimulant of airway smooth muscle relaxation
pathways in human airway smooth mucle (HASM). In these cells, the
physiological regulation of cAMP degradation is primarily through PDE4D
isoforms, with minor contributions from PDE3/4B isoforms (Billington,
Joseph et al. 1999; Le Jeune, Shepherd et al. 2002). Consistent with the
HASM cell culture experiments PDE4D is the major phosphodiesterase in
murine tracheal extracts and PDE4D knockout mice show reduced airway
smooth muscle contractility (Hansen, Jin et al. 2000; Mehats, Jin et al.
2003). In HASMs PDE4D5 seems most functionally relevant on account of
its marked upregulation in response to elevated cAMP (Le Jeune, Shepherd
et al. 2002; Hu, Nino et al. 2008). siRNA inhibition of PDE4D5 in HASMs
causes a significant reduction in time required for cAMP-induced FRET to
reach saturation in contrast to cells where PDE4D5 is uninhibited (Billington,
Le Jeune et al. 2008). PDE4D5 can be recruited to the β2AR by a β-arrestin
dependent mechanism. This allows for the possibility that localised
quenching of cAMP might happen and it would be coupled with arrestin-
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mediated desensitisation. Such a mechanism could be of significance in
long-term regulation of the β2AR (Perry, Baillie et al. 2002; Bolger, McCahill
et al. 2003).
Due to the importance of PDEs in regulating cAMP levels, PDE inhibitors
like theophylline are used with glucocorticosteriods therapy as a second- or
third-line treatment of asthma and COPD (Sullivan, Bekir et al. 1994;
Weinberger and Hendeles 1996; Lim, Jatakanon et al. 2000; Rennard 2004;
Spina 2008). Theophylline use is not favoured due to its narrow therapeutic
index and its unwanted drug interactions with other drugs that lead to
increase or decrease in serum concentrations of theophylline (BoswellSmith, Cazzola et al. 2006). It also blocks adenosine stimulation causing
many off-target effects. Thus careful monitoring of plasma levels of
theophylline is required while prescribing. Newer generation of PDE
inhibitors are isoform specific like PDE4-inhibitors roflumilast and cilomilast.
These inhibitors show promise in improving lung function and reducing
exacerbations of respiratory distress (Rabe 2011) but they still show offtarget effects and longer term trials are needed to determine if these have
an optimum place in COPD and asthma treatment (Cazzola, Picciolo et al.
2011; Chong, Poole et al. 2011).
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1.1.4. G-Protein Independent Arrestin Signalling
A number of proteins bind arrestins and are recruited to agonist-occupied
GPCRs, among them Src family tyrosine kinases (Luttrell, Ferguson et al.
1999; Barlic, Andrews et al. 2000; DeFea, Vaughn et al. 2000), members of the
c-Jun N-terminal kinase 3 (JNK3) and ERK1/2 mitogen-activated protein (MAP)
kinase cascades (DeFea, Zalevsky et al. 2000; McDonald, Chow et al. 2000;
Luttrell, Roudabush et al. 2001), Mdm2, an E3 ubiquitin ligase (Shenoy,
McDonald et al. 2001), the cAMP phosphodiesterases (PDE), PDE4D3/5
(Perry, Baillie et al. 2002), diacylglycerol kinase (Nelson, Perry et al. 2007), the
inhibitor of nuclear factor (NF)κB, IκBα (Witherow, Garrison et al. 2004), the
Ral-GDP dissociation stimulator (GDS), Ral-GDS (Bhattacharya, Anborgh et al.
2002), and the Ser/Thr protein phosphatase (PP)2A (Beaulieu, Sotnikova et al.
2005). It is via these interactions that arrestin binding to agonist-occupied
GPCRs confers unique signalling properties, opening up a broad realm of
previously unappreciated GPCR signal transduction.
Since arrestin binding completely uncouples G protein from the receptor, the
transmission of G protein-dependent and arrestin-dependent signals should be
mutually exclusive, at least at the individual receptor level. Comparison of the
ERK1/2 activation time course resulting from G protein signalling and from the
arrestin-dependent formation of an ERK1/2 activation complex on the
angiotensin AT1A, lysophosphatidic acid (LPA), type I parathyroid
hormone/PTH-related peptide (PTH1), and β2 adrenergic receptors
demonstrate that the onset of arrestin-dependent ERK1/2 activation coincides
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with the waning of G protein signalling and persists as receptors internalise
(Ahn, Shenoy et al. 2004; Gesty-Palmer, El Shewy et al. 2005; Gesty-Palmer,
Chen et al. 2006; Shenoy, Drake et al. 2006).
The arrestin-mediated and G-protein mediated signalling also tends to be
spatially discrete. In the ERK1/2 cascade, it is clear that receptors that form
stable complexes with arrestin, such as protease-activated receptor (PAR)-2,
angiotensin AT1A, vasopressin V2, and neurokinin NK-1 receptors, activate
ERK1/2 that accumulates in early endosomes along with the receptor (DeFea,
Zalevsky et al. 2000; Luttrell, Roudabush et al. 2001; Tohgo, Pierce et al.
2002). Unlike ERK1/2 activated by heterotrimeric G protein-mediated
pathways, signalsome-associated ERK1/2 does not translocate to the cell
nucleus and fails to induce a transcriptional response or stimulate cell
proliferation (DeFea, Zalevsky et al. 2000; Tohgo, Pierce et al. 2002). This
contrasts with receptors, such as the β2 adrenergic and LPA receptors, which
form transient complexes with arrestin that dissociate post internalisation
(Oakley, Laporte et al. 2000; Wei, Ahn et al. 2004; Milano, Kim et al. 2006;
Moore, Millman et al. 2007). Though, under physiologic conditions, arrestinmediated signalling commences concurrent with G protein activation, it is clear
that at least some arrestin-mediated signals do not require heterotrimeric G
protein activity. Data obtained using receptor mutants uncoupled from Gproteins and arrestin pathway-selectiveligands have shown that arrestindependent activation of ERK1/2 by the angiotensin AT1A, β2 adrenergic, and
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PTH1 receptors is G protein-independent (Azzi, Charest et al. 2003; Wei, Ahn
et al. 2003; Gesty-Palmer, Chen et al. 2006; Shenoy, Drake et al. 2006).
Studies of mice lacking nonvisual arrestin isoforms suggest considerable
functional redundancy among arrestin isoforms. Arrestin2- and arrestin3-null
mice are grossly normal, with phenotypes that become apparent only upon
treatment with pharmacological doses of GPCR agonists. Arrestin2-null mice
exhibit exaggerated cardiac sensitivity to β adrenergic agonists (Conner,
Mathier et al. 1997), whereas arrestin3-null mice demonstrate enhanced
morphine-induced analgesia and attenuation of opiate tolerance (Bohn,
Lefkowitz et al. 1999; Bohn, Lefkowitz et al. 2002). In each case, the
phenotypes are consistent with impaired GPCR desensitisation rather than the
loss of arrestin-mediated signalling.
1.1.5. Differences in Desensitisation of β2AR and Other GPCRs
Though β2AR is treated as a paradigm of GPCR desensitisation in textbooks
there are differences in desensitisation mechanisms of other GPCRs. D2 is a
dopaminergic GPCR. Locomotor hyperactivity induced by a D2 receptor agonist
like apomorphine, is reduced in arrestin3 knockout mice (Beaulieu, Marion et al.
2008). Likewise, the dopamine transporter knockout mice exhibit hyperactivity
on account of increased synaptic dopamine concentration. This is reduced
when these knockout mice are crossbred with arrestin3 knockouts, a
paradoxical result, since GPCR-mediated responses ought to be potentitated by
the loss of arrestin-dependent desensitisation. Similarly opioid peptides
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stimulate rapid internalisation of the µ opioid receptors while in contrast these
receptors fail to internalise post-prolonged treatment with saturating
concentrations of morphine, inspite of strong activation of receptor-mediated
signalling via heterotrimeric G proteins (Keith, Murray et al. 1996). Morphineactivated opioid receptors escape arrestin-dependent regulation via uncoupling
from heterotrimeric G proteins and Dyn-dependent endocytosis (Whistler and
von Zastrow 1998). Over expression of β-arrestin though causes increased
receptor internalisation and desensitisation. This suggests that under
physiological conditions the role of arrestin in agonist-induced desensitisation
could be different among GPCRs like D2 receptor, µ-opioid receptor and β2AR.
1.1.6. Biased Signalling
G protein-dependent and arrestin-dependent functions of many GPCRs can be
dissociated pharmacologically by ligands that exhibit functional selectivity or
“bias” favouring one pathway or the other (Kenakin 2002; Maudsley, Martin et
al. 2005; Violin and Lefkowitz 2007; Gesty-Palmer and Luttrell 2008; Luttrell
and Kenakin 2011). Conventional GPCR agonists and antagonists are believed
to activate or inhibit all aspects of signalling equally, whereas “biased agonists”
have the potential to change the signal output of a GPCR, thereby controlling
not only the quantity but also the quality of efficacy. A number of ligands have
been characterised that exhibit paradoxical reversal of efficacy (e.g., acting as
antagonists or inverse agonists of G protein signalling but behaving as agonists
with respect to arrestin recruitment and arrestin-dependent signalling). For
example, Sar1-Ile4-Ile8, an angiotensin AT1A receptor antagonist, promotes
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arrestin-inducedreceptor sequestration in the absence of significant G protein
activation (Holloway, Qian et al. 2002). Likewise, the PTH analog (DTrp12,Tyr34)PTH(7–34) is an inverse agonist for PTH1 receptor-Gs coupling
but promotes arrestin-dependent receptor internalisation (Gardella, Luck et al.
1996; Sneddon, Magyar et al. 2004). As a result, each is able to bring about
ERK1/2 activation that is arrestin-dependent and under conditions in which G
protein is not significantly activated (Gesty-Palmer, Chen et al. 2006). Likewise,
(±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2butanol (ICI118551), carvedilol and propranolol are β2AR ligands that show
partial inverse agonism with respect to Gs activation, and partial agonism for
the arrestin-mediated ERK1/2 activation (Azzi, Charest et al. 2003; Wisler,
DeWire et al. 2007; Drake, Violin et al. 2008). Our group has shown that
treatment of β2AR in HEK293 cells overexpressing receptor with saturating
concentrations of salmeterol does not lead to significant internalisation (Moore,
Millman et al. 2007). This phenomenon can be rescued by overexpression of
arrestin. Through kinetic modeling we show that the most probable explanation
for this is that salmeterol stabilizes a different β2AR state that in time shows
equivalent GRK phosphorylation but has reduced affinity for arrestin, thereby
reducing internalisation (Vayttaden, Friedman et al. 2010).
Studies have reported that the phospholipase C (PLC)-mediated inositol
phosphate (IP) accumulation and phospholipase A2(PLA2)-mediated
arachidonic acid (AA) release varies based on the identity of agonists
stimulating the human serotonin2A (5-HT2A) and 5-HT2C (Berg, Maayani et al.
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1998; Kurrasch-Orbaugh, Watts et al. 2003). 2,5-dimethoxy-4methylphenylisopropylamine (DOM) and 2,5-Dimethoxyphenylisopropylamine
(2,5-DMA) are examples of structurally close ligands. They differ only in the
methyl group at C4. Inspite of these similarities in structure 2,5-DMA and DOM
are good examples of biased agonists. For PLC-IP accumulation in 5-HT2C
receptor, both ligands are partial agonistsbut, DOM is a full agonist for PLA2AA release, and in contrast 2,5-DMA does not have a significant PLA2-AA
response. Taken together all these observations strongly suggest that the twostate receptor activation model is too simplistic and one requires the invoking
of multiple active states of the GPCRs that are differentially stabilized by
various ligands.
1.2. Modelling β2AR Regulation
Given the background of β2AR regulation explained in previous sections it
becomes increasingly clear that though the main features of β2AR desensitisation
are GRK/PKA-mediated phosphorylation, arrestin recruitment and PDE activation,
understanding which of these components is the dominant signalling module in
clinically observed tachyphylaxis is not easily tractable by traditional experimental
methods alone. This complication is because of 1) extensive use of different model
systems for studying human β2AR desensitisation, wherein results from one model
do not easily translate into another model; 2) simultaneous activation of various
pathways, necessitating pharmacological or genetic manipulations to silence other
signalling pathways; 3) isoform-specific differences of various signalling
components in tissue distribution and signalling; and 4) G-protein independent
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signalling. Thus it becomes necessary to first reduce all the complexities of β2AR
signalling into a consensus mathematical model that is advised by experimental
measurements of the system.
Reduction of the complexities of β2AR signalling into a consensus model might
seem counterintuitive but such model reduction has been helpful in physical
sciences. Borrowing an example from the physical sciences, light is modeled both
as a wave and as a particle because no one model can fully explain all the
observable properties of light. So reducing the complexity and modeling light as a
wave or a particle allows us to understand how light behaves under some
experimental conditions as a wave and in other conditions as a particle. Similarly in
order to understand β2AR desensitisation I will reduce the complexities of β2AR
signalling into three modules viz. 1) GRK/Arrestin-mediated β2AR desensitisation;
2) PKA-mediated β2AR desensitisation; and 3) PDE regulation. I will then test each
module against a defined set of experimental readouts and see if a combined
model can be created to explain β2AR desensitisation. In the process of model
building we will understand better the different modules of β2AR desensitisation.
My overall goal is to establish quantitatively the relevance of the major pathways of
desensitisation with endogenous β2AR receptor in cells of human airway origin.
Towards that end the work plan was to use HEK293 cells stably overexpressing
β2AR and obtain rates for key steps in GRK-, PKA- and PDE-mediated β2AR
desensitisation. Using these rates I would then develop a comprehensive model for
these pathways and once developed extend the model to HASMs where some of
the experimental measures are difficult to come by. A well validated and
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constrained model could then be used to understand the agonist specific
differences in signalling that allow differences in length of action of LABAs vs.
SABAs. This would help in teasing out agonist specific desensitisation pathways
that are responsible for tachyphylaxis in a clinical scenario.
1.2.1. Other Models of β2AR
The collision coupling model is one of the first βAR models, it suggests that
ligand activated receptors and G-proteins can collide and transiently couple to
activate the G-proteins (Tolkovsky and Levitzki 1981). More recent β2AR
models simulate downstream effects of isoproterenol-induced receptor
activation and match experimentally measured whole cell (Violin, DiPilato et al.
2008) or near-membrane cAMP (Xin, Tran et al. 2008). Other βAR models are
validated against more than one experimental readouts like isoproterenol
induced -cAMP response, -PKA activation, -PLB phosphorylation in
cardiomyocytes (Saucerman, Brunton et al. 2003) or - GRK
phosphorylation/dephosphorylation, -receptor trafficking in HEK293s
(Vayttaden, Friedman et al. 2010). Previous modelling work in the field has
largely ignored the interplay between the PKA and GRK mediated β2AR
desensitisation pathways. Our group in collaboration with Dr. Thomas Rich
(University of South Alabama) examined the cAMP turnover profiles in HEK293
cells expressing only endogenous β2AR. Their ordinary differential equation
(ODE) model described the importance of receptor levels, basal AC activity,
receptor desensitisation, and regulation of PDE activity in controlling cAMP
signals (Xin, Tran et al. 2008). This study did not model the GRK pathway in its
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full complexity, and examined desensitisation only at high agonist
concentrations at which the PKA component of β2AR desensitisation is
assumed to be not significant. Another limitation of the model was that there
was no correlation between receptor phosphorylation and receptor
desensitisation.
Another modelling study (Violin, DiPilato et al. 2008) captured the cAMP
profiles following β2AR activation as measured by using a fluorescent proteintagged EPAC sensor (ICUE2). This model did not include the PKA-mediated
β2AR desensitisation or the arrestin binding sequelae. The model used a
Monte Carlo method for simulating the kinetics of the cAMP profiles. In a Monte
Carlo method one uses a computer algorithm to randomly sample a
mathematical space. Since the Monte Carlo method is a statistical sampling
method, one of the caveats of this method is that if the modeller is not careful
the parameters used in the model might not necessarily match experimentally
determined values. For example, in this Monte Carlo model the rate constants
for PKA site phosphorylation and dephosphorylation were 0.0021 and 0.1103
sec-1, values that are ~100 and 1000 fold greater respectively from our
experimental values (Tran, Friedman et al. 2004; Tran, Friedman et al. 2007).
One effect of artificially setting the PKA dephosphorylation rate very high is that
the model will not be able to correctly capture the effects of PKA
phosphorylation on the system. These differences might explain their
conclusion that receptor inactivation by cAMP-dependent kinase is insignificant
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which is at variance from what has been previously reported (Clark, Kunkel et
al. 1988; Yuan, Friedman et al. 1994).
A major limitation of both these modelling studies was that cAMP profiles were
the only experimentally defined constraints on the model. In Chapter 3 I
describe my ODE model of β2AR desensitisation (Vayttaden, Friedman et al.
2010) that is constrained by six different types of experimental measurements
viz. GRK phosphorylation, dephosphorylation, receptor internalisation,
recycling, desensitisation and resensitisation. The model also describes the
arrestin binding sequelae and the GRK pathway in its full complexity. The major
conclusions of this modeling study will be discussed in Chapter 3.
1.2.2. Partial Agonist Models
Partial agonists are ligands that give sub-maximal receptor activation even at
receptor saturation. For β2AR, isoproterenol (Isuprel®) and epinephrine
(endogenous ligand) are examples of full agonists while salmeterol (Servent®)
and albuterol (Ventolin®, Proventil®) are examples of partial agonists. Barring
cyclopentylbutanephrine, the initial rate of GRK-mediated β2AR
phosphorylation correlates with the coupling efficiency of partial agonists
(January, Seibold et al. 1997; Tran, Friedman et al. 2004; Drake, Violin et al.
2008). Given the extensive clinical use of partial agonists especially as long
acting β-agonists I have extended my model (Vayttaden, Friedman et al. 2010)
described in Chapter 3 to model GRK-mediated β2AR phosphorylation in
response to a wide panel of partial agonists (Figure 4.1). Salmeterol (Figure
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1.3) is a weak β-agonist widely used as a complement to steroid therapy in the
treatment of asthma and COPD and available in the North American market as
AdvairTM which is the combination of a steroid (fluticasone propionate) and
salmeterol (Spencer and Jarvis 1999; Markham and Jarvis 2000; Nelson 2001;
Cowie, Boulet et al. 2007; McKeage and Keam 2009). It is equi-efficacious to
strong β-agonists in reversing bronchoconstriction and improving clincial
outcomes on chronic use.
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Figure 1.3 Structural Formula of Salmeterol.
Salmeterol has a salgenin head that binds the active site on the receptor and a hydrophobic
tail.
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Despite its clinical significance, salmeterol’s mechanism of β2AR activation and
regulation of downstream signalling in HASMs is not well understood. Following the
publication of salmeterol multicenter asthma research trial results (Nelson, Weiss
et al. 2006) Federal Drug Administration mandated a black-box warning for
salmeterol even though a salmeterol/steroid combination therapy was not part of
this meta-analysis. The text of the Advair black-box warning is as follows “Longacting β2-adrenergic agonists, such as salmeterol, one of the active ingredients in
ADVAIR DISKUS, may increase the risk of asthma-related death. Therefore, when
treating patients with asthma, physicians should only prescribe ADVAIR DISKUS
for patients not adequately controlled on other asthma-controller medications (e.g.,
low- to medium-dose inhaled corticosteroids) or whose disease severity clearly
warrants initiation of treatment with 2 maintenance therapies. Data from a large
placebo-controlled US study that compared the safety of salmeterol (Serevent®
Inhalation Aerosol) or placebo added to usual asthma therapy showed an increase
in asthma-related deaths in patient receiving salmeterol (13 deaths out of 13,176
patients treated for 28 weeks on salmeterol versus 3 deaths out of 13,179 patients
on placebo)”
The 8-12 hour persistence of salmeterol is responsible for its clinical effectiveness
(Beach, Young et al. 1992; Johnson, Butchers et al. 1993; Nials, Ball et al. 1994;
Palmqvist, Persson et al. 1997). This is also the Achilles heel of mechanistic
studies for salmeterol since it precludes washout experiments, and this too has
contributed to many controversies and misconceptions in the field (Duringer,
Grundstrom et al. 2009; Nino, Hu et al. 2009; Cooper, Kurten et al. 2011). A well
28

constrained and validated model of salmeterol action on β2AR could help in
clarifying the mechanism of salmeterol action especially since it is possible to
surmount difficulties of poor washout in silico. In Chapter 4 I discuss existing
models of salmeterol action. Briefly they are the microkinetic and exosite model.
The microkinetic model posits that lipophilicity of salmetereol leads to membrane
insertion of salmeterol and due to its delayed release there is a pool of salmeterol
around the receptor microenvironment (Anderson, Linden et al. 1994). The exosite
model posits that salmeterol binds the receptor to an exosite in addition to the
active site. This exosite binding is quasi-irreversible and allows for continued
retention of salmeterol near the receptor (Jack 1991). I combined the exosite and
microkinetic models with my validated model of GRK-mediated β2AR
desensitisation discussed in Chapter 3.
1.2.3. Combined Models of PKA-/GRK-/PDE-Mediated β2AR Regulation
In order to identify the dominant β2AR desensitisation pathways under different
therapeutic regimens it becomes necessary to create a unified model of PKA/PDE-/GRK-/Arrestin-mediated regulation of β2AR signalling. In Chapter 5 I
present very preliminary work towards this unified model. To create a
consensus model I combined my model of the GRK/Arrestin modules
(Vayttaden, Friedman et al. 2010) with that of the PKA/PDE modules that our
group had published previously (Xin, Tran et al. 2008). The unified model thus
created will be validated against experimental measurements of agonistinduced GRK-mediated β2AR-phosphorylation, PKA-mediated β2AR-
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phosphorylation, β2AR-dephosphorylation, -trafficking, -desensitisation, resensitisation and -cAMP profile.
1.3. Conclusion
The β2AR activates smooth muscle relaxation through both cAMP-dependent and
independent pathways. In order to understand why clinical tachyphylaxis happens
in response to β-agonists it becomes necessary to understand agonist specific
activation of the various β2AR desensitisation pathways. These studies are difficult
and extremely time consuming to perform in vivo or in vitro on account of multiple
isoforms and cross-reactions in signalling pathways. Towards that end I have
developed various computational models that explore different desensitisation
pathways and the effects of different β-agonists.
One of the limitations of the work presented in this thesis is that it is geared
towards understanding the effects of β-agonist mediated activation of β2AR in only
airway smooth muscle. When a patient is treated for asthma more than one tissue
type “sees” the β-agonist. β2AR is expressed in cells like mast cells, T cells etc. all
which play a role in the inflammatory component of asthma (Sitkauskiene and
Sakalauskas 2005; Anderson 2006; Deshpande and Penn 2006; Black, Oliver et al.
2009; Loza and Penn 2010). Additionally the patient on maintenance therapy for
asthma is treated with a combination of steroid and β-agonist so ideally the effect
of β-agonists should be studied in the background of the effects steroid treatment.
Inspite of the above described limitations as a first pass the models described here
could be used as tools for high throughput hypothesis testing of the β2AR
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regulatory components allowing us to select specific promising experiments to
follow through in vivo or in vitro.
Of most relevance to this thesis, the models described herein have resulted in
some novel conclusions: (i) receptor dephosphorylation at the membrane and
GRK-phosphorylated receptor recycling are required for proper β2AR kinetics
(Chapter 3, Figure 3.9); (ii) discovery of latent memory in the β2AR signalling
machinery (Chapter 3, Figures 3.11A, 3.12); (iii) realisation that receptor
internalisation was not required for β2AR resensitisation (Chapter 3, Figure 3.12);
(iv) salmeterol does not cause significant agonist-induced β2AR internalisation,
probably by destabilising the salmeterol/β2AR/arrestin complex; (v) reduced
stability of salmeterol/β2AR/arrestin complex might be the key property that
explains long action of salmeterol (Chapter 4, Figure 4.10); and (vi) it follows from
reduced arrestin binding to salmeterol/β2AR complex that salmeterol-induced
β2AR desensitisation would be predominantly mediated by the PKA pathway (PKAmediated β2AR phosphorylation and PDE activation). The preliminary work
towards modelling the combined effect of PKA-/GRK-/PDE-mediated regulation of
β2AR signalling is discussed in Chapter 5.
These models explain the basis of loss of efficacy during abuse of a rescue inhaler
and the reason for long action of β-agonists used in maintenance therapy. The
conclusions made herein reiterate the importance of modeling in studying β2AR
regulation since many of the observations made through modeling would not have
been easy to make solely by experiments.
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2. Materials and Methods
2.1. Experimental Methods
Data used in this thesis comes predominantly from experiments performed using
either HEK 293 cell lines with stable overexpression of β2AR at levels of 3–6
pmoles/mg membrane protein or HASMs that have β2AR at levels of ~ 0.03
pmoles/ mg membrane protein. Due to the low levels of β2AR in HASMs, receptor
phosphorylation could not be detected with available phosphosite-specific
antibodies. However, cAMP measurements could be performed in these cells. The
stable overexpression of the WT β2AR comes in three “flavours” viz. a) an Nterminal FLAG (DYKDDDDK) epitope tag (Tran, Friedman et al. 2007); b) an HA
(YPYDVPDYA) tag on the N-terminus (Morrison, Moore et al. 1996); and c) both an
HA (N-terminus) and a 6His (C-terminus) – Hβ2ARH (January, Seibold et al. 1997;
Seibold, January et al. 1998). These tags do not significantly perturb the
desensitisation parameters discussed in Tables 3.1 or 5.1 as measured by adenylyl
cyclase in cell-free membrane preparations (Morrison, Moore et al. 1996; January,
Seibold et al. 1997; Seibold, January et al. 1998; Iyer, Tran et al. 2006; Vaughan,
Millman et al. 2006; Tran, Friedman et al. 2007), therefore in the discussion I refer
to these stably expressing cell lines as expressing WT β2AR. Occasionally we
have used epinephrine instead of isoproterenol, and found no changes in the
desensitisation parameters at similar levels of receptor occupancy (Tran, Friedman
et al. 2004). The overexpression does affect dramatically the basal levels of cAMP
(much enhanced) and the time course and turnover of cAMP. Practically we find
that cAMP levels do not decrease in time, paradoxically it appears that the
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phosphodiesterase activity (as well as PKA activity – personal note from Peter
Fishman) is markedly increased to compensate for constitutive activity. This
problem is not discussed in any of the work by our group and others in the use of
overexpression lines. Therefore, to model and simulate cAMP turnover it is best to
use cells expressing either low or endogenous levels of receptor. On the other
hand it will be a test of the models to simulate the effect of a 100 fold increase in
receptors on cAMP turnover in the face of much higher PDE activity.
An interesting further paradox is that our basal level of GRK site phosphorylation is
almost undetectable (2-5% of the ISO stimulated levels, whereas the PKA site
phosphorylation shows a marked basal level about 15-25% of the stimulated level.
2.1.1. Intact Cell Membrane Dephosphorylation
HEK 293 cells stably overexpressing the WT β2AR were grown to confluency in
6-well plates. They were treated with 1µM isoproterenol dissolved in
ascorbate/thiourea, pH 7 at a final concentration of 0.1 mM ascorbate/1 mM
thiourea (AT) at 37°C for 30 secs. Post 30 sec saturating agonist challenge, the
medium was removed and replaced with medium containing 1.0 µM propranolol
(an antagonist). 30 sec of treatment with a saturating concentration of a full
agonist should lead to negligible (<0.5%) internalisation but close to 75%
maximal GRK phosphorylation. To stop all reactions, the medium was
aspirated, and the cells were rapidly washed with 1 ml of ice-cold HE buffer (20
mM HEPES and 1.0 mM EDTA, pH 7.7) and placed on ice. Cells were
solubilised by addition of 200 µl of ice cold solubilisation buffer (20 mM HEPES,
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pH 7.4, 150 mM NaCl, 0.9% dodecyl-β-maltoside, 20 mM tetrasodium
pyrophosphate, 10 mM NaF, 0.1 µM okadaic acid, 10 µg/ml each of
benzamidine, trypsin inhibitor, and leupeptin) to each well. The cells were
scraped into the solubilisation buffer, transferred to 1.5-ml microcentrifuge
tubes, and rocked for 30 min at 4°C. The solubilised extract was clarified by
centrifugation for 15 min at 15,000 rpm and 4°C. Post centrifugation, the
clarified supernatant of the cell extract was transferred to a new microcentrifuge
tube and treated with 150 units of PNGase F (2 hours, 37°C) to allow for
deglycosylation. Samples were then heated at 65°C for 15 min in SDS sample
buffer (2% sodium dodecyl sulphate, 10% glycerol, 100 mM Tris, pH 6.8,
bromphenol blue, and 10 mM dithiothreitol). 20 µL aliquots of samples were run
on 12% SDS-polyacrylamide gel electrophoresis and transferred to
nitrocellulose for immunoblotting. These nitrocellulose membranes were then
probed with phosphoserine-specific antibodies, anti-pS(355,356) for the GRK
sites on the β2AR. Post phosphoserine-specific antibody treatment the
membranes were washed twice and incubated with suitable dilution of goat antirabbit IgG horseradish peroxidase (Bio-Rad, Hercules, CA) and detected by
SuperSignal reagent. In order to determine receptor levels the immunoblots
were stripped and reprobed with a β2AR-specific rabbit anti-C-tail antibody. The
blots were imaged using a camera system (GeneGnome; Syngene, Frederick,
MD) or visualised on film using SuperSignal (Piercenet, Rockford, IL), and
bands quantified using Syngene software. The signal from the antipS(355,356)-specific antibodies were normalised to the corresponding signal

34

from anti-C-tail antibody. For averaging data across different dephosphorylation
experiments, the results were calculated as a fraction of the control
isoproterenol treatment followed by the means ± S.E.M.
2.2. Computational Methods
In this dissertation I have described 10 computational models of β2AR regulation.
These have been developed using a suite of different simulators and mathematical
solvers. The choice of simulators was motivated primarily by the extent of its use
among collaborators to allow for ease of model sharing followed by the ease of
model development. The choice of solvers was motivated by the ability to get an
efficient mathematical solution. Efficiency is used loosely here to reflect the
measure of the computational time invested in solving the system of equations to
get a reproducible solution, the faster we get a solution the more efficient is the
simulation. A reproducible solution won’t be significantly affected by change in time
steps of the simulation (c.f. Figure 2.1 for discussion of time steps) and it will be a
positive solution since negative concentrations is a physical impossibility. So an
attempt is made to use the largest time step at which a stable solution is attained
since the simulation time also tends to increase with the decrease in the time step,
and the simulated solution is usually better approximated to the actual curves at
smaller time steps. The point is to fix the time such that the simulation agrees as
closely as time permits with the experimental data.

35

Figure 2.1 Effect of Choice of Time Step.
A mockup of an experimentally determined time course is shown in grey. The polygonal
approximation of the curve is shown in different colours for the choice of various time steps –
green (large), orange (medium) and black (small).
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Table 2.1 A List of Models with the Simulator and Solver Used.
Model
Model Description

Simulator

Solver

Numbers
Runge-Kutta 4th
MATLAB
Order

GRK-mediated
1–6
regulation of β2AR

GENESIS/
Euler
Kinetikit

7–9

Salmeterol-induced

COPASI

GRK regulation of

GENESIS/

β2AR

Kinetikit

LSODE

Euler

LSODE/ Hybrid
GRK/PKA/PDE10

mediated regulation
of β2AR signalling

LSODE/ Hybrid
COPASI

Runge Kutta (a
variation of RungeKutta 4th Order)
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2.2.1. Choice of Simulators
2.2.1.1.

MATLAB

MATLAB® (MATrix LABoratory) is a proprietary numerical computing
environment developed by MathWorks (Natick, MA). It can be used for
matrix manipulations, data visualisation, algorithm development, data
analysis, and numeric computation. I used MATLAB R2008 for developing
the models described in Chapter 3 (models of GRK-mediated β2AR
regulation) because of legacy issues since our group had previously
implemented a model of PKA-/PDE-mediated β2AR regulation in MATLAB
(Xin, Tran et al. 2008). Due to extensive toolboxes MATLAB allows one to
perform numerical calculations and visualise results without the need for
time consuming programming. And because MATLAB has been in use since
1984 in academic research and industry, a wide online community is
available to help with potential problems. However, since MATLAB is an
interpreted language, it can be slow and poor programming practices would
compound the problem further. Modifying a pre-existing model and adding
new modules or removing old modules of reactions/equations is usually not
trivial. Also with MATLAB, users are subject to vendor lock-in making
sharing and viable reuse of models limited to the MATLAB language.
2.2.1.2.

GENESIS/Kinetikit

Kinetikit (Schutter 2001; Bhalla 2002; Vayttaden and Bhalla 2004) is a
graphical simulation environment that extends the capabilities of GENESIS
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(GEneral NEural SImulation System) (Touretzky 1989; Bower and Beeman
2007) to simulate large biochemical signalling pathways. Use of
GENESIS/Kintekit does not require any product registration. I have used
GENESIS/Kinetikit at the early stages of model development of all models
described in this thesis dissertation. The biggest advantage for me was the
ease of implementation of a variety of stimuli like paired pulses and agonist
washouts post activation. Usability of GENESIS/Kinetikit requires
experience to fully utilise the graphical user interface (GUI) and script
language. Also Kinetikit is computationally reliable and efficient. The reason
I didn’t use GENESIS/Kinetikit extensively beyond the initial model
development was because of the difficulty in portability of the models across
different operating systems. For the use of all features of GENESIS/Kinetikit,
one is dependent on the Linux environment and since our laboratory is
predominantly Windows rich this limited portability of the models. Also since
the GUI required familiarisation it wasn’t easy for anybody other than the
model author to follow the model development progress.
2.2.1.3.

COPASI

COPASI a graphical program that allows the simulation of biochemical
processes (Hoops, Sahle et al. 2006). COPASI can be downloaded freely
and in addition to deterministic and stochastic simulations of reaction
networks, it allows for flux analysis. I used COPASI due to its ease of use
and large suite of modeling analysis tools. The biggest advantage was the
ability to use the sliders feature that allowed for real-time, interactive
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parameter changes during simulations. This enhanced the model
development experience with experimentalists in our group settings.
COPASI is not without its quirks that do affect its usability. Unlike
GENESIS/Kinetikit COPASI does not have a very good network diagram
visualisation. While modelling very large networks, network diagram
visualization might not be “pretty” but it still is a very important tool in being
able to zoom in and find a reaction or associated parameters. In COPASI
one is limited to navigating a long table of alphanumeric characters to locate
a reaction or parameter of interest. While this mode of access is useful in
data entry it is not always efficient in data retrieval since model development
rarely proceeds in a linear fashion and there are additions and deletions of
reactions/species leading to “lack of order” in tables. Another drawback with
COPASI is that if the model uses assignments, rules and global quantities,
certain type of solvers cannot be used efficiently leading to extended
calculation times. For example, in my models there are many global
quantities like total GRK-phosphorylated receptor which is assigned the
value of sum total of all GRK-phosphorylated receptor species. The
simulated global quantity of total GRK-phosphorylated receptor is useful in
matching simulation results with experimental results of GRK
phosphorylation. Also combining parameter estimation with a variety of
stimuli like paired pulses and agonist washouts post activation is difficult.
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2.2.2. Choice of Solvers
2.2.2.1.

Euler

The Euler integration method (in GENESIS/Kinetikit) is an explicit method
for numerical integration of ordinary differential equations (ODEs) when
given its initial value. The advantage of this method is that it is
computationally simple. The disadvantage is that to reduce error in
estimations for stiff equations one will have to use very small timesteps
making it computationally inefficient. All models (1-10) were initially
implemented using GENESIS/Kinetikit 10 (Vayttaden and Bhalla 2004) and
an Euler solver on a PC running Red Hat Linux (Red Hat Corp., Raleigh,
NC).
2.2.2.2.

LSODE

The LSODE (Livermore Solver for Ordinary Differential Equations) is an
integration method for numerical integration of ODEs and can handle both
stiff and non-stiff equations. It was written by Linda R. Petzold and Alan C.
Hindmarsh and is the default method in COPASI to calculate timecourses.
Models 7-9 (described in Chapter 4) and model 10 (described in Chapter 5)
were implemented using COAPSI 4.6 and a Hybrid LSODE solver on a PC
running Windows 7 (Microsoft Corp., Redmond, WA).
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2.2.2.3.

Runge-Kutta

The Runge-Kutta methods are a group of implicit and explicit iterative
methods used in estimating solutions of ODEs. Different implementations of
Runge-Kutta methods are available in MATLAB, GENESIS/Kinetikit and
COPASI. Models 1-6 (described in Chapter 3) were implemented using
MATLAB R2008 and a 4th order Runge-Kutta solver on a PC running
Windows XP (Microsoft Corp., Redmond, WA) and model 10 (described in
Chapter 5) was implemented using COAPSI 4.6 and a Hybrid Runge-Kutta
solver on a PC running Windows 7 (Microsoft Corp., Redmond, WA).
2.2.3. Additional Model Details
The reactions for all models were written per the Law of Mass-Action (Guldberg
1864; Waage 1864; Waage and Guldberg 1864; Waage and Guldberg 2000
(Translation)) considering the system to exist in equilibrium. All analyses were
done using Microsoft Office Excel 2003/2007 (Microsoft Corp., Redmond, WA)
and plots were generated using GraphPad Prism 4/5 (GraphPad Software, Inc.,
La Jolla, CA).
2.2.4. Partial Agonist Simulations
2.2.4.1.

Relative Efficacy

Partial agonist-mediated activation of β2AR was simulated in Model 1 with
coupling efficacies of each agonist set relative to epinephrine (α) (c.f. Table
3.1, 4.1). The stated coupling efficacies/ efficiencies of various partial
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agonists were from previous measurements in HEK 293s that stably
overexpress WT β2AR (Tran, Friedman et al. 2004). The measurements of
partial agonist-induced β2AR phosphorylation and internalisation were done
at saturating agonist concentrations (Tran, Friedman et al. 2004; Moore,
Millman et al. 2007). In simulations of partial agonists, concentrations were
set equivalent to saturating epinephrine concentrations (10 µM) on account
of the fact that efficacies/coupling efficiencies were set relative to
epinephrine.
2.2.4.2.

Salmeterol Models

In Model 1, differential coupling efficacies for salmeterol- vs. epinephrineinduced β2AR activation was considered for salmeterol simulations. In
Models 8-10 in addition to differential coupling efficacies, simulations for
salmeterol mediated β2AR activation also invoked membrane accumulation
of salmeterol in the microkinetic model (Model 7), or a salmeterol-binding
exosite (Model 8), or both exosite and microkinetics (Model 9). The models
were written using previously described mathematical formalism for
salmeterol and competing agonist binding to β2AR (Szczuka, Wennerberg
et al. 2009) and post agonist-induced GRK-mediated β2AR regulation
(Vayttaden, Friedman et al. 2010).
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2.2.5. Simulation of Receptor Number Variation and Perturbations of Rate
Constants.
In order to account for experiments such as overexpression or knockdowns of
GRKs, phosphatases or arrestins, simulations of Models1-6 were performed by
2 to 50 fold variations of the relevant rate constants. In Model 7 the 100 fold
overexpression of β2AR in HEK293s as compared to HASMs is accounted for
by arbitrarily changing receptor levels from 100 µM (stable overexpressions) to
1µM (HASMs). The concentrations of receptor can also be estimated by
calculations for an “ideal” HEK293 cell approximated to a sphere as given
below.
Equation 2.1
Volume of an ideal HEK293 cell = 4/3 π R3 ~ 500 fL (when R = 5000 nm)
Equation 2.2
Volume of plasma membrane in an ideal HEK293 cell = 4/3 π (R3 - r3) ~ 3 fL
(when R = 5000 nm and r = 4990 nm, assuming a membrane thickness of 10
nm)
The total protein yield from a 10 cm dish ~ 1 mg and β2AR concentration ~ 3
pm/mg total protein. The approximate cell count in a confluent 10 cm dish is ~ 2
X 106 cells. This leads to an approximation of β2AR concentration to 3.0× 10-6
mole/L in a whole cell or 5.0× 10-4 mole/L in the membrane. This approximates
to a receptor number of 1 X 105/ cell.
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2.2.6. Sensitivity Analysis of Desensitisation and Resensitisation.
A univariate sensitivity analysis was carried out for Model 1 to test the effect of
variation in parameter values on the simulation results of desensitisation and
resensitisation. Barring the ligand binding and unbinding rates (which were left
unperturbed), all other rates were individually varied 2-, 5-, 10-, 20-fold around
the default rates (Table 3.1).
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3. GRK-Mediated β2AR Regulation
This chapter is adapted from “Quantitative Modeling of GRK-Mediated β2AR
Regulation.” Vayttaden SJ, Friedman J, Tran TM, Rich TC, Dessauer CW, Clark RB
(2010) PLoS Comput Biol 6(1): e1000647. doi:10.1371/journal.pcbi.1000647
I have modelled the GRK/Arrestin module of the β2AR regulation as it pertains to
experimental measures of agonist-induced GRK-mediated β2AR-phosphorylation,
β2AR-dephosphorylation, -trafficking, -desensitisation and -resensitisation (Figure 3.1).
Our group has previously shown that stable overexpressions of the WT β2AR in HEK
293 cells were suited for examining many aspects of the β2AR regulation process.
Most importantly, the duration and amplitude of β2AR desensitisation in these cells is
comparable with the endogenous receptor (Clark and Knoll 2002). In the stable
overexpression system, the EC50 of PKA-mediated β2AR phosphorylation is ~ 1000fold lower than the EC50 for GRK-phosphorylation of the β2AR. This allows us to
differentiate the GRK- and PKA-mediated β2AR desensitisation into separate
modules. We have previously shown that at high agonist concentrations GRK
accounts for the majority of β2AR desensitisation (Seibold, Williams et al. 2000). Table
3.1 lists the parameters used to model and simulate the consensus GRK pathway in
response to various agonists at different concentrations and durations. The data
simulated were from 90+ independent experiments on our stable overexpressions of
human β2AR in HEK 293 cells. Using a unique model to simulate the wide dataset
provided good modelling constraints. This ensured that the model applicability
extended over a wide repertoire of agonist-induced β2AR response.
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Figure 3.1 Reaction Diagram of the GRK-Mediated β2AR Regulation.
L is ligand; R* is active state of β2AR; Rs and Ri are surface/plasma membrane and
internalised β2AR; Rg is GRK-phosphorylated β2AR; Arr is arrestin. This reaction diagram
describes the default model for simulations using the rate constants as described in Table 3.1.
Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g001
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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Table 3.1 Parameters for GRK-Mediated β2AR Regulation Model
Reaction Name

Parameter (/min)

Reference/Rationale

Ligand (Agonist) On

k1f = k4b = k5b = 500

Ligand (Agonist) Off

k1b = k4f = k5f = 4

Rates used to achieve rapid ligand
binding so that it is not rate limiting.A

Ligand (Agonist) On (in
the presence of an
antagonist)

k1f = k4b = k5b = 0.005

Antagonist is assumed to behave as a
competitive inhibitor (Prichard and
Tomlinson 1986) so the agonist binding
rates are greatly reduced.

Ligand (Agonist) Off (in
the presence of an
antagonist)

k1b = k4f = k5f = 4

Agonist off-rates are unaffected in the
presence of an antagonist that behaves
like a competitive inhibitor

GRK Phosphorylation

k2f = α[R*]1.4

Initial rate of GRK phosphorylation on
treatment with 10 µM epinephrine = 0.71.4 /min (Tran, Friedman et al. 2004).B

GRK Dephosphorylation

k2b = k7f = k10f = 0.036

Phosphorylated receptor t1/2 = 18 min
(Tran, Friedman et al. 2007).

Arrestin On (to an
agonist-bound receptor)

k3f = 27.0

Rate of arrestin binding = 26.6 ± 5.9 /min
(Krasel, Bunemann et al. 2005)

Arrestin Off (from an
agonist-bound receptor)

k3b = 4.0

Rate of arrestin dissociation assumed to
match measured Kd.

Internalisation

k8f = 0.22

kf = 0.22 /min (Tran, Friedman et al.
2004).

Basal Internalisation

k11b = k12f = k13b =
0.0085

Rates used to match negligible basal
internalisation (Morrison, Moore et al.
1996).

Arrestin Off (from an
agonist-free receptor)

k6f = k9f = 11.0

Rate of arrestin dissociation = 10.86 ± 1.2
/min (Krasel, Bunemann et al. 2005).

Receptor Degradation

k14f = k15f = k16f = 0.004

t1/2 ~ 3–4 hours (Liang, Hoang et al.
2008).

Receptor Recycling

k11f = k13f = 0.09

kf = 0.09 /min (Tran, Friedman et al.
2004).

A

Off-rates for isoproterenol ≥ 4 /min (Mueller, Motulsky et al. 1988), epinephrine > 100 /min

(Krasel, Bunemann et al. 2005). For a Kd of 450 nM (epinephrine) and 283 nM (isoproterenol)
the calculated on-rates are very fast. Slowing down the forward-rates to 500 /min does not
affect the downstream events being simulated since they happen at a slower time scale. The
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ligand off-rate is not set at lower than 4 /min in order to avoid making it rate limiting for arrestin
dissociation.
B

α = Coupling efficiency relative to epinephrine; Isoproterenol is assumed to have the same

coupling efficiency as epinephrine since they are both full agonists. The relative coupling
efficiencies for partial agonists are as follows, Epinephrine = Isoproterenol = 1, Fenoterol =
0.66, Formoterol = 0.63, Terbutaline = 0.33, Zinterol = 0.33, Albuterol = 0.25, Salmeterol =
0.13, Dobutamine = 0.04 and Ephedrine = 0.03. [R*] = ([Rtotal] [Agonist]/([Agonist]+(Kd agonist));
[Rtotal] = 1; Kd epinephrine = 450 nM; Kd isoproterenol = 283 nM. Simulated phosphorylation rate = α
[R*]1.4 (for epinephrine); = α [R*]0.7 (for isoproterenol).
Model 1: All rates are set as described above, for the default model.
Model 2: k2b = k7f = 0 /min since this model disallows dephosphorylation at the plasma
membrane.
Model 3: k13f = 0 /min since this model disallows recycling of phosphorylated receptor.
Model 4: k10f = 0 /min since this model disallows dephosphorylation of the internalised
receptor.
Model 5: k10f = k13f = 0 /min since this model does not allow neither dephosphorylation of the
internalised receptor nor recycling of phosphorylated receptor.
Model 6: k2b = k7f = k13f = 0 /min since this model does not allow neither dephosphorylation of
the receptor at the plasma membrane nor recycling of phosphorylated receptor.
Table Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.t001
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
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TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647

50

3.1. Assumptions
3.1.1. Two State Model
Since all parameters described in Table 3.1 were obtained using full agonists
for the β2AR (epinephrine or isoproterenol), I assumed a simplified two state
model for β2AR activation. Here the plasma membrane bound inactive β2AR is
denoted by Rs and R*Ls denotes the agonist-induced active β2AR. I also
assumed ligand-induced β2AR activation since basal GRK Phosphorylation of
WT β2AR is negligible (Tran, Friedman et al. 2004; Vaughan, Millman et al.
2006; Tran, Friedman et al. 2007; Drake, Violin et al. 2008).
3.1.2. Ligand Binding
The off-rate for isoproterenol from the β2AR is ≥4 /min (Mueller, Motulsky et al.
1988) and for epinephrine >100 /min (Krasel, Bunemann et al. 2005). To
achieve the Kds for isopreoterenol (283 nM) and epinephrine (450 nM), the onrates have to be very fast. These fast rates were slowed down to 500 /min for
two reasons; (i) even at these reduced speeds ligand binding was about 18 fold
faster than the next fastest reaction so it did not affect the time course of the
downstream events being modelled; and (ii) at these reduced speeds very small
step sizes were not required to solve the differential equations using the RungeKutta solver (ODE23s) in MATLAB R2008 (MathWorks, Natick, MA).
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3.1.3. Ligand Dissociation
I assumed that the unbinding rates for agonist from β2AR were uninfluenced by
its arrestin binding or GRK phosphorylation status (Reactions 1b, 4f, 5f in
Figure 3.1). This is a simplification of the kinetics since arrestin binding
stabilizes a high-agonist affinity state of the receptor, prompting some authors
to characterise the receptor-arrestin complex as an alternative ternary complex
analogous to the ternary complex existing between agonist-receptor-G protein
in the absence of GTP (Gurevich, Pals-Rylaarsdam et al. 1997). This
simplification should not significantly affect the steady-state simulations of
receptor phosphorylation, internalisation, desensitisation since the experimental
measurements the simulations are constrained with are made under continuous
presence of high agonist. The effect of assuming equivalent ligand dissociation
rates for naïve, GRK-phosphorylated or arrestin bound receptor is that ligand
dissociation rates from arrestin bound-receptor (Reaction 5f in Figure 3.1) end
up being faster than normal leading to more rapid initial resensitisation post
agonist removal. Since we did not have rates of ligand dissociation from arrestin
bound receptor the model provided us a means to vary the ligand dissociation
rate for arrestin bound species and compare the simulated results to the
experimentally measured receptor resensitisation curve where the effects of this
reaction would be most dominant. Through our simulations we showed that a
ten-fold lower dissociation rate of ligand from arrestin-bound β2AR (Reaction 5f
in Figure 3.1) is required to match the initial resensitisation rates correctly
(Figure 3.3B).
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3.1.4. Receptor Activity
In the model I assumed that the GRK phosphorylated β2AR (Rgs, Rg*Ls in Figure
3.1) has reduced activity (0.7) compared to naïve β2AR (Benovic, Kuhn et al.
1987; Lohse, Andexinger et al. 1992; Tran, Friedman et al. 2007). This is a
simplification since the receptor can exist in any conformation in a wide
parameter space and each of the conformations would have its own activity.
The effect of this simplification of assigning the same activities for all “flavours”
of GRK-phosphorylated receptor is that the receptor activity profile would be
dependent on both time and concentration of agonists, so a one-size-fits-all
model would not easily match all data points. Thus the mismatches in simulated
receptor desensitisation and experimentally measured desensitisation (Figure
3.3A) could in part be because of this simplification. I also assumed that arrestin
binding or internalisation completely uncouples the receptors therefore those
species have no activity.
3.1.5. GRK-Phosphorylation Kinetics
I assumed that ligand activation of β2AR results in only a single event of GRK
phosphorylation where both serines 355 and 356 are simultaneously
phosphorylated. The anti-phosphosite antibody used in our β2AR
phosphorylation studies detects only dual phosphorylation of serines 355, 356.
Use of our antibody for studying GRK-mediated β2AR phosphorylation kinetics
has been validated by various groups (Tran, Friedman et al. 2004; Shenoy,
Drake et al. 2006; Violin, Ren et al. 2006; Pontier, Percherancier et al. 2008;
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Woo, Wang et al. 2009). The assumption of a single phosphorylation event and
equating Ser355,356 phosphorylation with “the” GRK phosphorylation event is a
simplification since we do know that in our cells the phosphorylation of Ser364
too is associated with GRK (Seibold, Williams et al. 2000). Also serine to
alanine substitution of serines 355, 356, and 364 eliminated receptor-level
desensitisation in the PKA- background (S261, 262A and S345, 346A) and
caused ~ 90% reduction in phosphorylation as assessed by 32P-prelabeling. So
there is at least a 10% receptor phosphorylation that cannot be attributed to the
currently identified GRK phosphorylation sites. Inspite of these limitations the
decision to assume a single event of GRK phosphorylation where both serines
355 and 356 are simultaneously phosphorylated is justified because 1) there
are no experimental readouts of individual phosphorylation sites available; 2)
the dual phosphorylation of S365, 366 correlates well with both a dose
response and time course of agonist treatment. The disadvantage of this
assumption is that it is no longer possible to project multi-phosphorylation states
of the receptor that could play a role in receptor sorting post-internalisation
selecting for recycling vs. receptor degradation. Also assuming a single
phosphorylation event prevents assigning multiple phosphorylation site specific
activities to the receptor, this could in turn affect the quality of simulation fits.
In my models 1-6 the rate of GRK-mediated β2AR phosphorylation is
dependent on the fraction of agonist-bound β2AR denoted by [R*], and coupling
efficiency of the ligand denoted by α. We’ve measured epinephrine induced
GRK-mediated β2AR phosphorylation to range from 0.7–1.4/min (Tran,
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Friedman et al. 2004). I assume that isoproterenol induced β2AR
phosphorylation rates will be in the same range since epinephrine and
isoproterenol have comparable efficacies.
We have previously shown that both the plasma membrane and endosomal
fraction of β2AR can undergo dephosphorylation (Iyer, Tran et al. 2006; Tran,
Friedman et al. 2007). Therefore I allow both plasma membrane and cytosolic
dephosphorylation of β2AR in my model (c.f. Footnote of Table 3.1).
3.1.6. Arrestin Kinetics
The arrestin on/off rates were obtained from experiments on fluorescently
tagged proteins (Krasel, Bunemann et al. 2005). I assumed that these
fluorescent tags did not affect the measured kinetics. The arrestin off-rate from
a ligand bound β2AR complex (Reaction 3b in Figure 3.1) was estimated to be
~4.0/min from previous measurements of the Kd (Gurevich, Dion et al. 1995).
3.1.7. Post-Internalisation Events
Consistent with the rapid on/off-rates and high Kds of epinephrine or
isoproterenol (Mueller, Motulsky et al. 1988; Devanathan, Yao et al. 2004) I
assumed ligand dissociation post β2AR internalisation to be very rapid. We
have previously shown negligible rates of basal β2AR internalisation (Morrison,
Moore et al. 1996). Since both basal and agonist induced β2AR internalisation
rates are slower than agonist dissociation I have collapsed β2AR internalisation
and post-internalisation agonist dissociation into a single step. This assumption
limits the usefulness of the model in simulating post-internalisation events on
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treating with certain partial agonists like Salmeterol which don’t easily dissociate
from the receptor (Jack 1991; Rong, Arbabian et al. 1999) and are postulated to
have low affinity for arrestin (Moore, Millman et al. 2007; Vayttaden, Friedman
et al. 2010).
In the GRK-mediated β2AR regulation model I allow arrestin-free internalised
β2AR to recycle independent of its phosphorylation status (Tran, Friedman et
al. 2007). Currently the precise mechanisms and pathways of β2AR
downregulation are unclear even though we have shown it to be biphasic
(Williams, Barber et al. 2000). Thus to simplify downregulation reactions in the
model I assume that all internalised β2AR species can undergo downregulation
(t1/2 = 3–4 hours) (Morrison, Moore et al. 1996; Williams, Barber et al. 2000;
Liang, Hoang et al. 2008).
3.1.8. Pseudo-First Order Kinetics
In HEK293s GRK2/5/6 levels exceeds even overexpressed β2AR levels by
approximately 100 fold (Tran, Jorgensen et al. 2007). We have also established
that the level of desensitisation in both HEK 293 cells with endogenous (30
fmol/mg) or overexpressed β2AR (3000 fmol/mg) is comparable. Arrestin levels
therefore should be sufficiently high to allow complete desensitisation even on
100 fold overexpression of β2AR. Others (Menard, Ferguson et al. 1997) have
shown that in comparison to four cell lines HEK 293 cells have relatively the the
highest levels of arrestin and GRK. In the light of the obvious excess of GRKs
and arrestin over β2AR I represent the second order reactions of GRK-
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mediated β2AR phosphorylation and arrestin binding to the β2AR as pseudofirst order reactions. These assumptions force us to use variation in rates of
arrestin binding or GRK-phosphorylation as a proxy to the effects of variation in
levels of arrestin and GRK.
3.2. Model Validation
My mathematical model of GRK-mediated β2AR regulation was validated against
six types of biochemical measurements (~ 90+ distinct experiments) in HEK 293
cells stably overexpressing the WT β2AR across a range of agonist concentrations
(Figures 3.2, 3.3, 4.1). The model validation results are discussed below.
3.2.1. GRK Phosphorylation
My model captured the main temporal features of GRK-mediated β2AR
phosphorylation across a wide range of epinephrine concentrations wherein the
stimulation was from 0–30 min (Figure 2.2A) and in response to a variety of
partial agonists (Figure 4.1). GRK-mediated β2AR phosphorylation was
measured in whole cell extracts as described here.
GRK phosphorylations of the β2AR at residues Serine (355, 366) were
determined using anti-phosphosite-specific antibodies (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) (Tran, Friedman et al. 2004). HEK293s
stably overexpressing WT β2AR were incubated with isoproterenol (Sigma, St.
Louis, MO), through different treatment times. Post-treatment the whole cell
protein was extracted with a solubilisation buffer and then incubated with
Peptide N-glycosidase F (New England Biolabs, Ipswich, MA) to remove
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glycosyl residues. This was followed by a treatment with SDS sample buffer
prior to running on polyacrylamide gel electrophoresis. Following the gel
transfer, the levels of GRK site phosphorylation were determined by western
blots. First, the phosphorylation data was normalised to β2AR levels and then to
allow inter-experimental comparison it was normalised to the maximum
phosphorylation with saturating concentrations of epinephrine.
GRK-mediated β2AR phosphorylation was simulated by selecting dosage and
duration of ligand treatment corresponding to the experimental measurements.
The sum total of Rgs, Rg*Ls, ArrRgs, ArrRg*Ls, ArrRgi and Rgi (Figure 3.1)
was plotted as a percentage of total β2AR against the experimentally measured
GRK phosphorylated β2AR (Figure 3.2A).
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Figure 3.2. Comparisons of Experimental Results with Simulations of the Model.
Panels A–D: Comparisons of simulations (continuous lines) of the model shown in Figure 2.1,
with experimental data obtained in HEK 293 cells stably overexpressing FLAG WT β2AR
(discrete data points). (A) Time course of GRK phosphorylation of the receptor on treatment
with different concentrations of epinephrine (Tran, Friedman et al. 2004). (B)
Dephosphorylation of the GRK phosphorylated site on the receptor after 5 min treatment with
either 1.0 µM or 10 nM ISO (red bar) followed by addition of propranolol (blue bar) and
measure of loss of GRK site phosphorylation. Phosphorylated receptor is expressed as a
percent of phosphorylation achieved at the end of 5 min treatment with either agonist
concentration (Tran, Friedman et al. 2007). (C) Recycling of the receptor after 20 min
treatment with 1µM isoproterenol followed by rapid washout of agonist (Morrison, Moore et al.
1996). (D) Internalisation of β2AR on treatment with various concentrations of isoproterenol as
indicated. Surface receptor is measured by the loss of [3H]CGP-12177 (Tran, Friedman et al.
2007).
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Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g002
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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3.2.2. Dephosphorylation
Dephosphorylation of the GRK phosphorylated β2AR was simulated across a
100 fold agonist concentration range as shown in Figure 3.2B.
Dephosphorylation of the GRK-phosphorylated WT β2AR was measured in
whole cell extract as described below.
In dephosphorylation experiments HEK293s stably overexpressing WT β2AR
were treated for 5 min with either 1.0 µM or 10 nM isoproterenol. Post agonist
treatment the cells were washed and incubated with medium containing 0.1 µM
propranolol (Sigma, St. Louis, MO) (Tran, Friedman et al. 2004). The loss of
GRK site phosphorylations at Serine (355, 366) was then assayed using
western blots as discussed in Section 3.2.1. In the dephosphorylation
experiments, phosphorylation at 5 min with different agonist concentrations was
normalised as maximum phosphorylation foreach concentration.
The dephosphorylation simulations had two parts - the first part dealt with
ligand-induced GRK-mediated β2AR phosphorylation, and the second part dealt
with the antagonist treatment allowing for β2AR dephosphorylation.
Concentrations of all species of β2AR for the second part of the simulation were
initialised to the terminal state from the first simulation. During the second
phase of the simulations the ligand on rates were reduced 100,000 fold (to
mimic competitive binding with an antagonist). On completion of the
simulations, the sum total of Rgs, Rg*Ls, ArrRgs, ArrRg*Ls, ArrRgi and Rgi
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(Figure 3.1) was plotted as a percentage of total β2AR against the
experimentally measured GRK phosphorylated β2AR (Figure 3.2B).
3.2.3. Recycling
β2AR recycling was measured by [3H]CGP-12177 binding, post a 20 min
isoproterenol treatment followed by a wash as described here. HEK 293s stably
overexpressing WT βAR were treated with 1 µM agonist (isoproternol) through
20 min to maximise internalisation. Post ligand treatment, the cells were
washed to remove ligand and incubated for the times indicated at 37°C to allow
recycling. Surface β2AR levels were assayed using [3H]CGP-12177 binding as
described in the previous section (Seibold, Williams et al. 2000). The measure
of β2AR at the surface at time 0 was normalised as 100% surface βAR.
Recycling was simulated similar to dephosphorylation as described in 3.2.2
since both experiments involved two perturbations during the course of an
experiment. On completion of the β2AR recycling simulations the sum total of
Rs, R*Ls, Rgs, Rg*Ls, ArrRgs and ArrRg*Ls (Figure 3.1) was plotted against
the experimentally measured surface β2AR with the surface receptor at time
zero normalised to 100% (Figure 3.2C).
3.2.4. Internalisation
HEK 293s stably overexpressing WT βAR were treated with varying agonist
(isoproterenol) concentrations through different treatment times. Post ligand
treatment and washing, receptor internalisation was measured in intact cells
using [3H]CGP-12177 (20 nM) binding (Tran, Friedman et al. 2007). [3H]CGP62

12177 is a hydrophilic antagonist that binds only surface (plasma membrane)
βAR at 0–4°C. The binding assay is conducted ±1µM alprenolol (Sigma, St.
Louis, MO), a β2AR antagonist used to determine non-specific binding of
[3H]CGP-12177. The measure of surface β2AR at time 0 was normalised as
100% surface β2AR for different agonist concentrations.
On completion of the internalisation simulations the sum total of Rs, R*Ls, Rgs,
Rg*Ls, ArrRgs and ArrRg*Ls (Figure 3.1) was plotted against the experimentally
measured surface β2AR with the surface receptor at time zero normalised to
100% (Figure 3.2D).
3.2.5. Desensitisation
The β2AR desensitisation measurements (Figure 3.3A) were made in HEK 293
cells that either stably overexpressed WT β2AR or a β2AR lacking the two PKA
consensus sites (S261, 262A and S345, 346A termed PKA-). PKA- was used to
eliminate the effects of PKA-mediated β2AR desensitisation (Seibold, Williams
et al. 2000). Desensitisation of β2AR stimulation of AC was performed as
described below.
HEK 293s that stably overexpressed either WT βAR or a β2AR lacking the two
PKA consensus sites (S261, 262A and S345, 346A) were treated with various
concentrations of agonist (isoproterenol). Post washout of ligand, membrane
fractions were separated using sucrose step gradients. Desensitisation was
measured as the increase in EC50 for isoproterenol stimulation of AC relative to
controls and the results were calculated as fraction activity remaining (Tran,
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Friedman et al. 2007). Through our previous studies we have shown that there
is a 35% decrease in Vmax from downstream effects, most likely on AC (Whaley,
Yuan et al. 1994; Seibold, Williams et al. 2000). So in the model of receptorlevel GRK-mediated desensitisation described here we ignore these Vmax
changes. The model described in Chapter 5 does address downstream effects
due to PDE activity but even this model ignores Vmax effects due to
postranscriptional modifications of AC.
On completion of the simulation run, activity was calculated as the weighted
sum of Rs, R*Ls, Rg*Ls and Rgs normalised to initial receptor activity. The
weighting of the active β2AR species was decided as discussed above in 3.1.4.
Simulated β2AR activity was plotted against the experimentally measured
active β2AR (Figure 3.3A). Since the model lacked PKA-mediated β2AR
regulation it underestimated early (first two minutes) desensitisation post-ligand
treatment for the WTβ2AR, but there was significant concurrence with
experimental data over longer treatment times.
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Figure 3.3. Validation of the Model with Two Sets of Experimental Results.
Validation of the simulations (continuous lines) of the model shown in Figure 3.1, with
experimental data obtained in HEK 293 cells stably overexpressing the FLAG WT β2AR
(discrete data points). (A) Desensitisation of β2AR stimulation of adenylyl cyclase after
treatment with 10 µM isoproterenol. Inset shows β2AR desensitisation on stimulation with 30
nM isoproterenol. Red – simulated results; Black – WT cells; Blue - cells stably overexpressing
β2AR lacking PKA phosphorylation sites (PKA-). At lower concentrations the model matches
PKA- desensitisation more closely since it does not include PKA-mediated β2AR
desensitisation. (B) Resensitisation of the β2AR stimulation of adenylyl cyclase. WT β2AR
were stimulated with 1µM isoproterenol for 15 min, followed by addition of metoprolol as
described in 3.2.6. Dotted line shows simulated % activity of the β2AR when ligand
dissociation from arrestin-bound receptor complex is reduced by ten-fold.
Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g003
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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3.2.6. Resensitisation
The β2AR resensitisation experiments (Figure 3.3B) were done in HEK 293
cells that stably overexpressed WT β2AR as described here.
In order to measure resensitisation of WT β2AR, propranolol could not be used
for the blockade of isoproterenol stimulation as described for desensitisation in
Section 3.2.5, because its rate of dissociation from the receptor was too slow to
allow for resensitisation time course measurements. To avoid this handicap we
used a low affinity antagonist of the βARs like 100 µM metoprolol (240 nM Kd)
(Sigma, St. Louis, MO) (Tran, Friedman et al. 2007). Post different
resensitisation times cells were washed free of metoprolol, and membranes
were prepared and assayed for isoproterenol stimulation of AC (Tran, Friedman
et al. 2007). The measure of membrane AC activity at time 0 is normalised as
maximum activity in desensitisation and resensitisation experiments.
β2AR resensitisation was simulated in two parts, as described previously for
dephosphorylation (3.2.2) and recycling (3.2.3). At the end of the simulation run,
activity was calculated as the weighted sum of Rs, R*Ls, Rg*Ls and Rgs
normalised to the initial receptor activity. The weighting of the active β2AR
species was decided as discussed above in 3.1.4. As an artefact of the rates
(Reaction 5f, Figure 3.1) used in the default model (Table 3.1, Model 1) there is
initially a rapid increase in resensitisation. This artefactual spike can be
removed on lowering the rate of agonist dissociation from an arrestin-bound

66

β2AR complex (Reaction 5f, Figure 3.1) by ten-fold which is in line with the
increased apparent stability of this complex (Gurevich, Dion et al. 1995).
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Figure 3.4. Correlation of Simulated Surface Arrestin with G Protein Independent
ERK Activation.
pERK data (Shenoy, Drake et al. 2006) matches initial accumulation of simulated surface
arrestin (Arrs + ArrRg*Ls; Figure 2.1). The discrepancy in latter time points might be due to
activation of ERK phosphatases which is not explicitly modelled. TYY mutants are uncoupled
from G protein so the ERK phosphorylation seen is independent of G protein activation.
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3.2.7. Arrestin-Dependent ERK Activation
There have been a number of experiments demonstrating G proteinindependent signalling that appears to depend on arrestin scaffolding of MAPK
cascades (Pierce, Luttrell et al. 2001; Song, Coffa et al. 2009). Since I did not
use any arrestin signalling data to create the model, the ability to match
arrestin-mediated ERK signalling data would be an independent validation of
my model. I have compared the simulated time course of surface arrestin
species viz. sum total of Arrs and ArrRg*Ls (Figure 3.1) with recent data
(Shenoy, Drake et al. 2006) showing the G protein independent activation of
ERK (Figure 3.4). For the early times of agonist stimulation there is good
correlation of simulated surface arrestin with G protein independent ERK
activation. The discrepancy in latter time points might be due to activation of
ERK phosphatases which is not explicitly modelled.
3.2.8. Sensitivity Analyses
I subjected the model to a univariate sensitivity analyses by varying individual
rates over a twenty-fold range and studying its effects on the simulated β2AR
desensitisation and resensitisation under conditions described in 3.2.5 and
3.2.6. The motivation to run sensitivity analyses on desensitisation and
resensitisation were, 1) these were functional readouts of the signalling
pathway; 2) these were experiments that validated the behaviour of the insilico
β2AR signalling pathway; and 3) test for the robustness of the model by
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checking for the dependence of modeled behavior on choice of reaction
parameters.
The simulations were carried out as described in Methods 2.2.6 and the results
plotted as the difference from the average experimental value at each time
point.
In the simulated β2AR desensitisation experiments the model was significantly
sensitive to perturbations of only three rates (Figure 3.5). Decreasing GRKmediated β2AR phosphorylation (k2f, Table 3.1) reduced the desensitisation at
earlier time points. Reduction of arrestin affinity for the β2AR-agonist complex
(k3f, k3b, Table 3.1) decreased desensitisation at later time points. These
observations were consistent with the model design.
The interpretation of the sensitivity analysis for β2AR resensitisation (Figure
3.6) is not straightforward because I’d to first desensitise the system. The predesensitisation affected the initial simulated values of resensitisation. Reducing
ArrRg*Ls internalisation (k8f, Table 3.1) decreased β2AR desensitisation at 15
min (see conditions in Figure 3.3B) leading to a higher baseline at the start of
resensitisation causing an overestimate of initial resensitisation. Perturbing
internalisation rates did not have any additional effects on latter time points of
resensitisation. Increasing β2AR recycling (k11f, k13f, Table 3.1) reduced the
internalised pool of β2AR and caused an overestimation of β2AR
resensitisation. As a quality control measure the sensitivity analyses did not
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reveal any unexpected surprises in the model behavior and it was robust over a
wide range of perturbations.
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Figure 3.5. Univariate Sensitivity Analyses of the Model for Desensitisation.
Panels A–Q: Simulated isoproterenol (10 µM) induced β2AR desensitisation over a twentyfold variation of individual rates. Negative values indicate a simulated measurement higher
than experimental measure.
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Figure and Figure Legend Source:
http://dx.doi.org/10.1371/journal.pcbi.1000647#pcbi.1000647.s002
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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Figure 3.6. Univariate Sensitivity Analyses of the Model for Resensitisation.
Panels A–Q: Simulated β2AR resensitisation post 15 min isoproterenol (1 µM) treatment over
a twenty-fold variation of individual rates. Negative values indicate a simulated measurement
higher than experimental measure.
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Figure and Figure Legend Source:
http://dx.doi.org/10.1371/journal.pcbi.1000647#pcbi.1000647.s003
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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3.3. Model Description
The ordinary differential equations for the GRK-mediated β2AR regulation based
on the Laws of Mass Action are given below.
Equation 3.1
dR  dt   k



k

k   R L 

R

k

 R

Equation 3.2
dR L dt   k

k   R L 



k  R

k  R L 

Equation 3.3
dR L dt   k 

k  R L 

k

k   R L 

k  ArrR L 

k  R  

Equation 3.4
dArrR L dt   k 

k

k  ArrR L 

k  R L 

ArrR  

k  ArrR L 

k  ArrR  

Equation 3.5
dArrR  dt   k 

k

k



Equation 3.6
dR  dt   k 

k

k

 R  

k  R L 

k



R  

k  ArrR  

76

Equation 3.7
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In the equations 3.1-3.10 kxf and kxb denote the forward and backward rates for
the reaction number denoted by x. Rs = β2AR on the plasma membrane; R*Ls =
Agonist bound β2AR on the plasma membrane; Rg*Ls = Agonist bound, GRK
phosphorylated β2AR on the plasma membrane; ArrRg*Ls= Agonist and arrestin
bound, GRK phosphorylated β2AR on the plasma membrane; ArrRgs = Arrestin
bound, GRK phosphorylated β2AR on the plasma membrane; ArrRgi = Arrestin
bound, GRK phosphorylated β2AR in the internalised compartments; Rgi = GRK
phosphorylated β2AR in the internalised compartments; Ri = β2AR in the
internalised compartments; Rdegraded = Degraded β2AR in the cytoplasm.
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3.4. Model Results and Discussions
GRK and arrestin isoforms have been frequently targeted for overexpression or
knockdown in different cells types (Ahn, Nelson et al. 2003; Penela, Ribas et al.
2003; Reiter and Lefkowitz 2006; Violin, Ren et al. 2006; Luo, Busillo et al. 2008).
These proteins also differ in their overall expression levels and localisation (Zhang,
Barak et al. 1997; Komori, Cain et al. 1998). They also undergo post-translational
modifications which might affect its activity (Lin, Krueger et al. 1997; Lin, Chen et
al. 2002; Penela, Ribas et al. 2003; Shenoy, Drake et al. 2006). Given that there is
wide variability in the activity or level of theseβ2AR regulatory proteins in different
cell types I was interested in the effect of this variability on the modelling results. I
varied GRK-mediated β2AR phosphorylation and arrestin β2AR binding rates over
a hundred-fold range around rates mentioned in Table 3.1 and plotted its effects on
β2AR phosphorylation, desensitisation and internalisation over a 0–30 min time
course.
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Figure 3.7 Simulated Effects of Varying Rates of GRK Phosphorylation and
Arrestin Binding.
Panels A–C: Simulated effects of hundred-fold variation in GRK phosphorylation rates on (A)
phosphorylation, (B) internalisation and (C) desensitisation. D–E: Simulated effects of
hundred-fold variation in arrestin binding rates on (D) phosphorylation, (E) internalisation and
(F) desensitisation. Experimental data as given in Figure 3.2A, C, and Figure 3.3A.
Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g004
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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3.4.1. Variation in GRK-Mediated β2AR Phosphorylation Rates
Steady states of GRK phosphorylated β2AR were unaffected over hundred-fold
variation in GRK phosphorylation rates (Figure 3.7 A-C) on treatment with
saturating concentration (10 µM) of epinephrine. Initial GRK phosphorylation
was significantly affected only by a decrease in the phosphorylation rates
(Figure 3.7A). Since β2AR phosphorylation measurements in most GRK
overexpression and knockdown studies are performed with saturating agonist
concentrations at steady state, my model suggests that this would increase the
risk of false negative results. A more exacting measure for the effects of GRK
overexpression and knockdown experiments would be an estimate of the initial
rates of GRK-mediated receptor phosphorylation at sub-saturating ligand
concentrations. To test this assertion I simulated the effects of hundred-fold
variations in rates of GRK-mediated β2AR phosphorylation following treatment
with 50 nm epinephrine. Figure 3.8 clearly shows that effects of variations in
GRK-mediated β2AR phosphorylation are more pronounced at subsaturating
ligand concentrations.
Since GRK phosphorylation of the β2AR is a pre-requisite for agonist-induced
arrestin binding (Krasel, Bunemann et al. 2005) and internalisation, only
perturbations that markedly affected GRK phosphorylation affected
internalisation. Therefore only lowering the GRK-mediated β2AR
phosphorylation rates had any marked effect on the initial rates of
internalisation, with little effect on the maximum internalisation (Figure 3.7B).
The effects on desensitisation were similar to phosphorylation albeit they were
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phase shifted on account of these being sequential events (Figure 3.7C).
Therefore effects of variations in GRK-mediated β2AR phosphorylation on both
internalisation and desensitisation are best studied at early time points with
subsaturating ligand concentrations.
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Figure 3.8 Simulated Effects of Varying Rates of GRK Phosphorylation.
Effect of variations in GRK levels or activity on phosphorylation at subsaturating concentration
of epinephrine (50 nM) is simulated by ten-fold up or down variations in GRK phosphorylation
rates.
Figure and Figure Legend Source:
http://dx.doi.org/10.1371/journal.pcbi.1000647 #pcbi.1000647.s004
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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3.4.2. Variation in Arrestin β2AR Binding Rates
I varied the rates of arrestin binding β2AR over a hundred-fold range and
studied the effect it had on GRK-mediated β2AR phosphorylation,
internalisation and desensitisation (Figure 3.7D-F). Perturbing arrestin binding
rates did not have significant effects on the initial maxima of GRK-mediated
β2AR phosphorylation (Figure 3.7D). This was expected and served as a good
sensitivity analyses since arrestin binding occurs only subsequent to GRKmediated β2AR phosphorylation. Reducing arrestin binding rates (Figure 3.7E)
decreased internalisation by approximately 40% within 5-10 minutes post
agonist treatment, whereas increasing these rates did not significantly increase
the maximum internalisation at 30 minutes. The effect of variations in arrestin
binding rates on β2AR desensitisation was similar to that of internalisation in
that only a reduction in arrestin binding rates decreased desensitisation.
3.4.3. Effects of β2AR Trafficking and the Cellular Location of
Dephosphorylation
The possibility of cell surface dephosphorylation of the GRK phosphorylated
β2AR and the recycling of the phosphorylated β2AR has been a contentious
issue (Yu, Lefkowitz et al. 1993; Pippig, Andexinger et al. 1995; Krueger, Daaka
et al. 1997; Iyer, Tran et al. 2006; Kelly 2006). Our group has shown that 1)
blocking internalisation does not prevent β2AR dephosphorylation (Iyer, Tran et
al. 2006), and 2) that β2AR dephosphorylation can occur even at undetectable
levels of internalisation (Tran, Friedman et al. 2007). I have determined GRK
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site β2AR dephosphorylation rates at the membrane to be ~0.04/min per
method described in 2.1.1.
Other GPCRs such as f TRH receptors (Jones and Hinkle 2005) and D1
dopamine receptors (Gardner, Liu et al. 2001) also undergo dephosphorylation
at the plasma membrane. To investigate the effects of membrane
dephosphorylation and phosphorylated receptor recycling I created six different
models (Figure 3.9A-F) that vary different reactions as described in the footnote
of Table 3.1. For ease of visualisation of the cellular distribution of the GRK
phosphorylated β2AR, I plotted the total (black), the cytosolic (blue), and the
surface (red) GRK phosphorylated β2AR.
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Figure 3.9 Simulated Effects of Phosphatase Location and Recycling of
Phosphorylated β2AR on Receptor Dephosphorylation.
HEK 293 cells stably overexpressing WT β2AR were treated for 5 min with 1 µM ISO (red bar)
followed by washout and addition of 1 µM propranolol (blue bar). Experimental data (Tran,
Friedman et al. 2007) are shown as discrete points with standard errors and the simulations
are shown as continuous lines. The black lines are the total phosphorylated receptor, red
indicates the phosphorylated receptor on the plasma membrane and blue indicate internalised
levels of phosphorylated β2AR. (A) Model 1 allows for dephosphorylation of both the
internalised and plasma membrane bound receptor along with recycling of phosphorylated and
dephosphorylated receptor. (B) Model 2 disallows plasma membrane dephosphorylation but
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allows both dephosphorylation of the internalised receptor and recycling of phosphorylated
receptor. (C) Model 3 allows for dephosphorylation of both the internalised and plasma
membrane bound receptor but limits recycling to only dephosphorylated receptor. (D) Model 4
allows for dephosphorylation only at the plasma membrane and also allows recycling of
phosphorylated receptor. (E) Model 5 allows for dephosphorylation only at the plasma
membrane and disallows recycling of phosphorylated receptor. (F) Model 6 allows for
dephosphorylation only after internalisation and prevents recycling of phosphorylated receptor.
Model 1: All rates are set as described in Table 3.1, for the default model.
Model 2: k2b = k7f = 0 /min since this model disallows dephosphorylation at the plasma
membrane.
Model 3: k13f = 0 /min since this model disallows recycling of phosphorylated receptor.
Model 4: k10f = 0 /min since this model disallows dephosphorylation of the internalised
receptor.
Model 5: k10f = k13f = 0 /min since this model does not allow neither dephosphorylation of the
internalised receptor nor recycling of phosphorylated receptor.
Model 6: k2b = k7f = k13f = 0 /min since this model does not allow neither dephosphorylation of
the receptor at the plasma membrane nor recycling of phosphorylated receptor.
Figure and Figure Legend Source adapted from:
http://dx.doi.org/10.1371/journal.pcbi.1000647.g005
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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In Figure 3.9A I modelled our default reaction topology that allowed for both
receptor dephosphorylation at the cell surface and phosphorylated receptor
recycling. I contrasted this with Figure 3.9F where I modelled a reaction
topology that did not allow for both plasma membrane dephosphorylation and
recycling of phosphorylated receptor. This was in keeping with the prevalent
view around early 2000s (Krupnick and Benovic 1998; Billington and Penn
2003). I showed that under these conditions the system failed to achieve more
than 50% β2AR dephosphorylation which was discordant with our experimental
measurements (Tran, Friedman et al. 2007). Increasing the cytosolic
dephosphorylation rate did not help in rescuing the simulated
dephosphorylation curves. Thus through modeling I was able to show that the
prevalent model of early 2000s was not able to explain dephosphorylation
measurements done in our lab.
Since there were two reactions being contested viz. receptor dephosphorylation
at the plasma membrane and phosphorylated receptor recycling, I decided to
explore the effects of disallowing one of each reaction and cytosolic
dephosphorylation in the remaining models to ensure that a random variation of
these reaction topologies wouldn’t match our experimental data (Figure3.9B-E).
Of the models tested Figure 3.9C and D showed that two models matched the
measured dephosphorylation kinetics in addition to my default model. This
therefore required additional testing of the two models to see if they matched
other experimental measurements of our β2AR over expression system.
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Preventing recycling of GRK phosphorylated β2AR did not skew the simulated
rate of β2AR dephosphorylation (Figure 3.9C). I subjected Model 3 to further
tests (Figure 3.10A-E) against other experimental measurements and showed
that in the absence of GRK phosphorylated β2AR recycling, the model did not
match the experimental measurements of internalisation (Figure 3.10B),
recycling (Figure 3.10C) and resensitisation (Figure 3.10E). In the light of these
observations it was clear that Model 3 could not represent the topology of
reactions for β2AR in our over expression HEK293s.
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Figure 3.10 Comparisons of Five Experimental Results with Simulations of
Model 3 and 4.
Through panels A–E I test alternate models 3 and 4 to see how well they match other
experimental readouts of the β2AR signalling system besides dephosphorylation (c.f. Figure
3.9C, D). Comparisons of simulations (continuous lines) of model 3 (A–E) and model 4 (F–J),
with experimental data obtained in HEK 293 cells stably expressing the WT β2AR (discrete
data points). (A, F) Time course of GRK phosphorylation of the receptor on treatment with 50
nM isoproterenol (Tran, Friedman et al. 2004). (B, G) Internalisation of the β2AR on treatment
with 1 µM isoproterenol. Surface receptor is measured by the loss of [3H]CGP-12177. (C, H)
Recycling of the receptor after 20 min treatment with 1µM isoproterenol followed by rapid
washout of agonist (Morrison, Moore et al. 1996). (D, I) Desensitisation of β2AR stimulation of
adenylyl cyclase post treatment with 10 µM isoproterenol. (E, J) Resensitisation of the β2AR
stimulation of adenylyl cyclase. WT β2AR were stimulated with 1µM isoproterenol for 15 min,
followed by addition of metoprolol as described in 3.2.6.
Figure and Figure Legend Source:
http://dx.doi.org/10.1371/journal.pcbi.1000647#pcbi.1000647.s005
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“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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There was a good match between the measured and simulated
dephosphorylation rates in Figure 3.9D where I had allowed recycling of the
GRK phosphorylated β2AR and dephosphorylation only at the plasma
membrane. I subjected Model 4 to further tests in Figure 3.10F-J. I showed that
in the absence of cytoplasmic β2AR dephosphorylation, a 30 fold higher plasma
membrane dephosphorylation rate is required to match the experimentally
measured phosphorylation kinetics (Figure 3.10F). Absence of cytosolic β2AR
dephosphorylation is at odds with experimental observations of the β2AR
(Sibley, Strasser et al. 1986; Pippig, Andexinger et al. 1995; Tran, Friedman et
al. 2007). In the light of these observations it was clear that Model 4 could not
represent the topology of reactions for β2AR in our over expression HEK293s.
This model cannot be summarily rejected for other GPCRs though where
significant cytosolic dephosphorylation might not occur under physiological
conditions.
I allowed for solely plasma membrane dephosphorylation and prevented
phosphorylated receptor recycling in Model 5 (Figure 3.9E). Under these
conditions the dephosphorylation rates were significantly reduced. Thus of the
six models designed, only one model viz. model 1 (Figure 3.1, Table 3.1, Figure
3.9A) accounted for six different types of experimental measurements (Figures
3.2, 3.3). This model was functionally unique and random variation in topologies
of dephosphorylation and recycling reactions could not recapitulate all
experimental measurements of our β2AR over expression system in HEK293s.
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3.4.4. Frequency Coding
Most of the studies discussed until now were performed in the presence of
saturating agonist concentrations for long durations. Such a prolonged
exposure rarely occurs under normal physiological conditions without
pharmacological intervention. Rather based on the target tissue the β2AR
“sees” different frequencies and amplitudes of stimuli. Synaptic β2AR “sees”
high norepinephrine concentrations in a pulsatile fashion (Trendelenburg,
Gaiser et al. 1999; Stjarne 2000) due to the small synaptic volumes, rapid
removal and reuptake of norepinephrine. In contrast to the synaptic stimuli, the
bloodstream concentrations of agonist post epinephrine secretion from the
adrenal gland are much lower but for relatively longer periods.
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Figure 3.11 Simulations of the Effects of Frequency Modulation.
In these panels I describe the effect of varying the frequency of stimulation on surface (black),
phosphorylated (red) and active (green) receptor species. (A) Rapid stimulation with a train of
1 µM isoproterenol pulses for 0.5 min followed by a 0.5 min washout. Note that this achieves
more than 80% desensitisation with only 20% internalisation. (B) This panels shows the
results of a 5 min stimulation with 1.0 µM isoproterenol and a 5 min washout. (C) Simulation of
30 min stimulation with 50 nM isoproterenol followed by washout of 30 min. This panel shows
that even with low β2AR occupancy (15%) the prolonged stimulation time gives substantial
desensitisation.
Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g006
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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I explored the effects of varying frequencies of agonist stimulation on my model.
The first scenario shown here is that of stimuli at ~ 0.0167 Hz which is
equivalent to 30 s bursts of agonist followed by 30 s washouts. I assumed that
the washouts were perfect and allowed for instantaneous agonist dissociation
from the receptor (Figure 3.11A). Under this stimulation pattern almost 100%
GRK phosphorylation (red – GRK phosphorylated β2AR) is achieved with only
20% internalisation (black – surface β2AR) but about 80% desensitisation
(green – active β2AR). Post agonist washout, resensitisation was rapid due to
fastdissociation of arrestin from the receptor. In spite of this near complete
recovery, during subsequent pulsatile activation of the β2AR, the signalling
machinery “remembers” previous agonist exposure and desensitises much
more strongly on subsequent exposures. This memory of prior stimuli can be
attributed to the accumulation of the GRK phosphorylated β2AR due to slower
dephosphorylation.
In Figure 3.11B I stimulate the system with a continuous 5 min long delivery of
1µM isoproterenol followed by a 5 min wash and subsequent restimulation for 5
min. Under this stimulus profile close to 95% β2AR is desensitised with ~ 50%
β2AR internalised. In Figure 3.11C I tested the response of the β2AR system on
prolonged exposure to sub-saturating levels of agonist. I simulated the
response to 30 min delivery of 50 nM isoproterenol followed by 30 min wash
and restimulation. Under longer periods of ligand treatment (Figure 3.11B, C)
the resensitisation was biphasic (c.f Figure 3.3B). The rapid phase of
resensitisation is dependent upon arrestin dissociation from the receptor while
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the slower phase is dependent upon receptor recycling and dephosphorylation
(Tran, Friedman et al. 2007).
The phenomenon of latent memory that I described in Figure 3.11A was only
observed at higher frequencies of agonist stimulation. For longer periods of
stimulation (Figure 3.11C), as might be seen during treatment with a strong,
stable agonist in diseases such as asthma, receptor recycling would play a
significant role in resensitisation.
3.4.5. Latent Memory
Having previously shown in Figure 3.11A that the β2AR signalling machinery
could “remember” previous stimuli I wanted to explore the effects of variation in
inter-pulse duration (time between paired pulse stimulation), β2AR
dephosphorylation and arrestin dissociation on this latent memory. I simulated a
paired pulse pattern of β2AR activation with 1µM isoproterenol (Figure 3.12A).
Even on rapid, near complete β2AR resensitisation, the system remembered
previous stimuli and showed stronger desensitisation in response to
subsequent stimuli (“active” β2AR- green lines, Figure 3.12A). The latent
memory can be attributed to stockpiling of GRK phosphorylated β2AR on the
surface (red). Pre-phosphorylation of the β2AR primes the system for faster
arrestin binding to surface receptor (blue) on subsequent agonist activation,
leading to increased desensitisation. Increasing the inter-pulse duration
weakened the memory (Figure 3.12B), since it allowed the slow rate of
dephosphorylation to catch up. The memory survived beyond 30 min post first
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stimulus. An extreme 50 fold increase in dephosphorylation rates was required
to erode the memory of the previous stimuli (Figure 3.12C).
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Figure 3.12 Basis for “Cellular Memory” in the β2AR Signalling Machinery.
(A) Simulation of activation of β2AR by paired pulses of 1 µM isoproterenol. Higher
desensitisation is obtained for the second and third pulse. Colours indicate simulated receptor
species as indicated in the figure. (B) Decay in memory of prior stimuli on increase in interpulse period from 1–120 min. (C) Effect of up to 50 fold increase in surface dephosphorylation
rates on memory of prior stimuli. Default dephosphorylation rate is 0.036/min. (D) Effect of
arrestin-β2AR complex stability on desensitisation time courses simulated by varying arrestin
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dissociation rates from the ligand-free complex on the surface. Default arrestin surface
dissociation rate from the ligand-free complex is 11/min.
Figure and Figure Legend Source: http://dx.doi.org/10.1371/journal.pcbi.1000647.g007
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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Figure 3.13 Sensitivity of Simulated “Cellular Memory” to the Stability of
Arrestin-Receptor/Ligand Complex.
Simulation of activation of β2AR by paired pulses of 1 µM Isoproterenol. Higher
desensitisation is obtained for the second and third pulse even on 100 fold increased stability
of the arrestin-receptor/ligand complex.
Figure and Figure Legend Source:
http://dx.doi.org/10.1371/journal.pcbi.1000647#pcbi.1000647.s006
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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Some GPCRs have a higher affinity for arrestin than β2AR causing a slower
release of arrestin from the receptor post internalisation (Moore, Milano et al.
2007). To investigate the effects of slow arrestin release from β2AR on latent
memory I decreased the dissociation rate of arrestin from the β2AR (Figure 3.1,
Table 3.1; k3b, k6f, k9f) thereby mimicking a high affinity complex. The time
required for resensitisation was directly proportional to the affinity of arrestin for
the β2AR (Figure 3.12D). Next I increased the stability of the ligand/β2AR
/arrestin complex by a 100 fold reduction in the ligand off-rate (Figure 3.1, Table
3.1; k5f). This did not diminish the extent of memory, but it did increase the
recovery time between each paired pulse (Figure 3.13). In summary, the
predicted latent memory was due to (i) slow β2AR dephosphorylation (0.036
/min); and (ii) rapid arrestin dissociation from ligand free β2AR (11.0 /min).
3.4.6. Model Limitations
My model ignores effects of adenylyl cyclase or PDE regulation and PKA
mediated β2AR phosphorylation. In the absence of the PKA/PDE module the
current model fails to capture the behaviour of the β2AR signalling machinery at
low agonist concentrations as shown in Figure 3.3A inset (red bar graphs). Our
group has shown that at high agonist concentrations GRK phosphorylation
appears to decrease PKA site phosphorylation of the β2AR (Vaughan, Millman
et al. 2006). Prestimulation of PKA mediated β2AR phosphorylation with
forskolin on the other hand does not affect GRK mediated β2AR
phosphorylation (Tran, Friedman et al. 2004). So clearly there is some interplay
between PKA and GRK phosphorylation of the β2AR and this cannot be
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explored in the current model. I have modelled only receptor-level
desensitisation and as a consequence omitted downstream regulatory events
like adenylyl cyclase regulation.
On account of lack of relevant kinetic data my model ignores multi-site
phosphorylation of the receptor in that it considers phosphorylation and
dephosphorylation of S365, 366 as a single event and ignores phosphorylation
at other sites by GRK or PKA. As a consequence of this simplification this
model cannot be used to explore effects of phosphosignature on receptor
sorting and varied receptor activity.
In this model I collapse internalisation of arrestin-bound, GRK-phosphorylated
ligand-bound β2AR and post-internalisation ligand dissociation into the same
step since internalisation is slower than ligand dissociation rates for full agonists
like epinephrine/isoproterenol. This model in its current state cannot be used to
simulate post-internalisation effects on treatment with a partial agonist like
salmeterol that quasi-irreversibly bind to the β2AR.
The simplistic ligand-induced two-state receptor activation model used here can
be used to credibly simulate a variety of biochemical events that the receptor
undergoes like GRK phosphorylation/dephosphorylation, receptor trafficking,
desensitisation/resensitisation. This representation of receptor activation is not
amenable to studying biased signalling of the receptor on account of lack of
representation of other signalling states of the receptor and lack of downstream
signalling proteins like the elements of the MAPK cascade.
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Due to the use of pseudo-first order reactions to simulate ligand -, arrestin- and
GRK-binding the receptor the model in its current form cannot be used to study
the effects of prolonged membrane accumulation of lipophilic ligands like
salmeterol and formoterol that could persist even after internalisation of the
receptor. This model also cannot explore effects of agonist treatment on GRK
and arrestin trafficking and recruitment to the plasma membrane bound
receptor.
I have shown that preventing plasma membrane receptor dephosphorylation
and recycling of the GRK phosphorylated receptor is antithetical with my
modeling and our previous experimental results. A point to note is that my
model does not have a significant basal internalisation. Agonist-independent
internalisation does occur in GPCRs like the melanocortin MC4 receptor
(Mohammad, Baldini et al. 2007) and cannabinoid CB1 receptor (McDonald,
Henstridge et al. 2007). Our group has shown that in HEK293s there is no
detectable basal internalisation of the β2AR (Morrison, Moore et al. 1996).
Others have detected agonist-independent internalisation in HeLa cells
transiently transfected with M3R or β2AR (Scarselli and Donaldson 2009). It
needs to be examined if agonist-independent β2AR internalisation occurs in
other cell lines, and if it does the current model would hold true only for β2AR
signalling in HEK293s.
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4. Partial Agonist Models
Agonist-induced activation of a GPCR leads to a change in the relative orientations of
the transmembrane helices leading to induction of a signal transduction function. The
efficiency with which these ligands induce the downstream signal transduction is called
coupling efficiency. Partial agonists are ligands that give sub-maximal receptor
activation on account of lower coupling efficiency even at receptor saturation. For
β2AR, isoproterenol (Isuprel®) and epinephrine (endogenous ligand) are examples of
full agonists while salmeterol (Servent®) and albuterol (Ventolin®, Proventil®) are
examples of partial agonists. Except for cyclopentylbutanephrine, the initial rate of
GRK-mediated β2AR phosphorylation is proportional to the coupling efficiency of
partial agonists (January, Seibold et al. 1997; Tran, Friedman et al. 2004; Drake, Violin
et al. 2008).
4.1. Relative Efficacies
I used the GRK-mediated β2AR regulation model developed in Chapter 3 to model
partial agonist induced GRK-mediated β2AR phosphorylation. To do this I set the
coupling efficiencies of the partial agonist relative to epinephrine/isoproterenol (α in
Table 2.1 for parameter k2f). The relative coupling efficiencies for partial agonists
are given in Table 4.1.
Figure 4.1A shows that the simulated time course of salmeterol and albuterol
induced GRK-mediated β2AR phosphorylation matches experimental data over 30
minutes. In figure 4.1B I show that the simulation results match well the GRK-
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mediated β2AR phosphorylation at 2 min normalised to 10 µM epinephrine. These
results are additional validation for Model 1 presented in Chapter 3.
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Table 4.1. Relative Coupling Efficiencies and Kds of β-Agonists
Coupling Efficiencies
Agonist

a

Kd (nM) b

Relative to Epinephrine
Epinephrine

1

450

Isoproterenol

1

283

Fenoterol

0.66

133

Formoterol

0.63

5

Terbutaline

0.33

1835

Zinterol

0.33

8.6

Albuterol

0.25

420

Salmeterol

0.13

<2

Dobutamine

0.04

589

Ephedrine

0.03

2674

a

The relative coupling efficiencies are calculated as described by our group
previously (Tran, Friedman et al. 2004).
b

Kds as estimated in HEK293 cells stably overexpressing β2AR.
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Figure 4.1 Comparison of Simulated Time Course of GRK Site Phosphorylation
with Experimentally Measured Phosphorylation in Response to Various
Agonists.
(A) The simulated time course of GRK site phosphorylation of the β2AR in response to
various agonists is compared with experimentally measured phosphorylation (Tran, Friedman
et al. 2004). (B) Comparison of simulated and experimentally measured GRK-mediated β2AR
phosphorylation at 2 min of agonist treatment normalised to phosphorylation achieved with 10
µM epinephrine (Tran, Friedman et al. 2004).
Figure and Figure Legend Source:
http://dx.doi.org/10.1371/journal.pcbi.1000647#pcbi.1000647.s001
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman J, Tran
TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1): e1000647.
doi:10.1371/journal.pcbi.1000647
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4.2. Previous Models of Salmeterol Action on the Receptor
Salmeterol is a partial agonist that is extensively used clinically in maintenance
therapy of asthma along with a steroid. Due to the clinical importance of salmeterol
there have been a few phenomenological models of salmeterol. All models of
salmeterol action must reconcile with two important phenomena of salmeterol
action, viz. (i) long action (8-12 hours) as described in the section above; and (ii)
reassertion of salmeterol action following first treatment with antagonist (that fully
inhibits salmeterol action), and second, washout of antagonist without addition of
new salmeterol (Ball, Brittain et al. 1991; Anderson 1993). Additionally clinical
models of salmeterol must also explain the reason for delayed onset of salmeterol
action (Ball, Brittain et al. 1991; Johnson, Butchers et al. 1993; Nials, Coleman et
al. 1993). In contrast to slow onset of salmeterol action in patients and tissue
explants, salmeterol shows no noticeable lag in monolayer cell culture experiments
(McCrea and Hill 1993; Clark, Allal et al. 1996; McCrea and Hill 1996). Therefore,
we have not attempted to model the torturous path of salmeterol to the relevant
sites of action on the receptor.
A detailed discussion of the merits of the different models of salmeterol action can
be found elsewhere (Anderson, Linden et al. 1994; Szczuka, Wennerberg et al.
2009). Briefly, salmeterol action has been explained by three models. Salmeterol
is lipohilic and reversibly incorporates in the plasma membrane, resulting in a
partition of drugs between a membrane and an aqueous phase (Rhodes, Newton
et al. 1992). Due to membrane partitioning of salmeterol, the membrane can act as
a salmeterol reservoir and this forms the basis of the microkinetic model (MM)
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(Anderson, Linden et al. 1994) (Figure 4.2). Due to the high membrane partitioning
of salmeterol and its slow rate of release from the membrane, t1/2 = 25 mins
(synthetic membranes) – 3 hours (tracheal strips) (Rhodes, Newton et al. 1992;
Austin, Barton et al. 2003) it is posited that salmeterol reaches the receptor by
lateral diffusion through the membrane (Anderson, Linden et al. 1994) since by the
time salmeterol traverses the length of the airways to reach the target bronchii it
would have bound to the membrane on account of its lipophilicity.
Per the exosite model (EM) (Figure 4.4) the saligenin head of salmeterol (Figure
1.2) and the hydrophobic phenylalkoxyalkyl side chain binds the β2AR at two
spatially distinct sites. The site of saligenin head binding is identified as the active
site and the site of hydrophobic phenylalkoxyalkyl side chain binding is called an
exosite. In the exosite model tethering of the phenylalkoxyalkyl chain to the exosite
is quasi-irreversible while the binding of the saligenin head to the active site is
rapidly reversible. This model also allows agonist or antagonist binding to the
active site when the exosite is occupied by salmeterol’s hydrophobic tail (Figure
6.1). To allow the flipping in and out of the saligenin head from the active site, the
exosite has been posited to be in the central core of the β2AR (Jack 1991). Both
site directed mutagenesis studies involving replacement of β2AR central domains
with β1AR (Green, Spasoff et al. 1996; Isogaya, Yamagiwa et al. 1998) and
photoaffinity labeling with [125I]iodoazido-salmeterol (Rong, Arbabian et al. 1999)
lend credence to the idea that the exosite is further into the transmembrane
domains toward the cytosol than the active site.
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The rebinding model posits that a high local concentration of salmeterol is
maintained on account of rapid rebinding (Szczuka, Wennerberg et al. 2009). This
model wouldn’t be able to explain the reassertion phenomenon when a competing
ligand is present without invoking another mechanism to retain salmeterol in the
proximity of the receptor.
Given the importance of salmeterol in treating asthma and COPD (as discussed in
Section 1.3) I developed phenomenological models to describe the effects of
membrane retention of salmeterol, exosite binding or a composite of the two
(combined model - CM). I then coupled these models to an adaptation of the
GRK-mediated β2AR regulation model developed in Chapter 3 and then tested
them to see if properties of salmeterol long action and reassertion still held true.
4.2.1. Model Assumptions
4.2.1.1.

Isoproterenol Partitioning (Valid for MM/EM/CM)

I presume that isoproterenol “sees” the plasma membrane as an inert
substratum for the β2AR. As a consequence of this there is no partitioning of
isoproterenol from the aqueous phase into the plasma membrane. Washout
of isoproterenol from the aqueous phase results in no lingering free
isoproterenol concentration in the plasma membrane. To mimic addition of
isoproterenol in an in silico experiment I initialise free isoproterenol
concentration in the aqueous phase to the concentration used in the in vitro
experiment. To mimic washout of isoproterenol in an in silico experiment I
buffer free isoproterenol concentration in the aqueous phase to zero.
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4.2.1.2.

Salmeterol Partitioning (Valid for MM/CM)

I have modelled salmeterol partitioning into the plasma membrane as a first
order reaction. Partitition coefficient for a molecule is defined as the ratio of
concentrations of a molecule in the phases of a mixture of immiscible
solvents at equilibrium. Membrane based partition coefficient (Kp(mem)) for
salmeterol has been determined to be 22500 from unilamellar liposomes
(Rhodes, Newton et al. 1992; Lombardi, Cuenoud et al. 2009). Using
dioleoyl phosphatidylcholine it has been estimated that under ideal
conditions the association coefficient (Ka) would be ~ 1.24 X Kp(mem)(Rhodes,
Newton et al. 1992). Thus the Ka of salmeterol would be ~ 27900.
The t1/2 for salmeterol release from membranes ranges between ~ 60 min
from unilamellar liposomes to ~ 180 min from multilamellar liposomes
(Rhodes, Newton et al. 1992). I used the t1/2 of 180 min to calculate a rate of
salmeterol release from the membrane because (i) the t1/2 is comparable to
that from tracheal strips (Austin, Barton et al. 2003), and (ii) partition
coefficients for other systems are not affected by lamellarity of membranes
(Rhodes, Newton et al. 1992). Using a t1/2 of 180 min the rate of release of
salmeterol from the plasma membrane (krel) is approximated to 0.004 /min.
Once krel is known the rate of plasma membrane association for salmeterol
(kin) can be approximated to 107 /min from Ka.
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4.2.1.3.

Salmeterol Exosite Binding (Valid for EM/CM)

I have assumed that the rate of salmeterol binding to the exosite is same as
the rate of plasma membrane association for salmeterol and hence both are
denoted by kin with a t1/2 ~ 0.006/min. This is a simplification since based on
the rate of appearance of the increase in basal adenylyl cylase activity in
washed membranes after salmeterol treatment of intact cells we have
estimated a t1/2 ~ 0.14/min. (Clark, Allal et al. 1996)
Also I have assumed that the rate of release of salmeterol from the exosite
is the same as the rate of salmeterol release from the plasma membrane,
and hence both are denoted by krel. This too is a gross oversimplification
since while we do know that the t1/2 of release of salmeterol from synthetic
liposomes is ~180 min (Rhodes, Newton et al. 1992) krel from the exosite is
quasi-irreversible making a measure of release of salmeterol from the
exosite difficult (Clark, Allal et al. 1996). Further this rate is inextricably
mixed in with release from the membranes. As a consequence of these
simplifications it is possible to run the simulations for a shorter period of time
and it is possible to compare the microkinetic and exosite models on the
same timescales.
Salmeterol can bind either the active site or the exosite of a naïve receptor.
Again for ease of simulations I have ignored the receptor state that has
salmeterol bound to the active-site alone (c.f.Figure 4.4. Reactions 6 and 7).
Since I am exploring the effects of long term salmetereol action, at the time
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courses being simulated, both active and exo-site of the receptor will be
occupied.
4.2.1.4.

Ligand Binding (Valid for MM/EM/CM)

Since we had an estimate of Kd for epinephrine to be ~ 450 nM (Vayttaden,
Friedman et al. 2010) the off-rates were calculated to give the appropriate
Kd. The on-rates of isoproterenol were assumed to be similar to epinephrine
and then using a Kd of ~ 283 nM (Vayttaden, Friedman et al. 2010)
appropriate off-rates were calculated. I assumed that salmeterol binds β2AR
on the active site at the same rate as isoproterenol. Based upon the Kd for
salmeterol (2 nM) (Rong, Arbabian et al. 1999), off-rates were calculated. In
the exosite model Sal:REam (salmeterol bound only to the exosite) can
transition into Sal:REAm (salmeterol bound to both active site and exosite on
the β2AR). This transition is a first order reaction and its rate must match the
second order rate for salmeterol binding β2AR (8.4e+08 /M.min). I estimated
the first order transition rates to be ~ 20 /min by matching the t1/2 for both
reactions at saturating agonist concentration. Using this calculation we note
that the off rate for salmeterol is about 1400 times slower that for
isopreoterenol/epinephrine.
4.2.1.5.

Ligand Dissociation (Valid for MM/EM/CM)

I ignored ligand dissociation from membrane bound, GRK phosphorylated
β2AR with or without arrestin in the larger models that have microkinetics or
exosite binding introduced into the GRK-mediated β2AR regulation. This
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was done to reduce the number of receptor states and reactions. The
reactions that I have ignored have negligible fluxes under saturating agonist
concentrations since under these conditions GRK phosphorylation and
arrestin binding are favoured. Therefore I’ve validated the model only to
GRK phosphorylation under saturating levels of agonist. Due to these
modifications, under washout conditions there will be an exaggeration of
membrane retention of agonists and residual receptor activity on account of
accumulation of ligand bound GRK-phosphorylated β2AR. Arrestin kinetics
will be unaffected by these modifications. It is not known if the assumption of
saturating concentration of salmeterol might bear out under pharmacological
conditions. The recommended dose of Advair HFA gives 42 µg of
salmeterol base which amounts to 60.90 µg of salmeterol xinafoate
(GlaxoSmithKline 2008). Peak plasma concentrations from 21 µg of
salmeterol base is about 510 pg/mL but due to the lipophilicity of salmeterol
it is anybody’s guess what the actual concentrations are in the plasma
membranes.
4.2.2. Microkinetic Model (MM)
The hallmark of the microkinetic model (Figure 4.2) is the partitioning of salmeterol
into the plasma membrane which then serves as a reservoir for prolonged
salmeterol action (Anderson, Linden et al. 1994). Table 4.2 lists the parameters
used in my representation of the microkinetic model. Figure 4.3 shows that this
representation of the microkinetic model can recapitulate both long action and
reassertion of salmeterol post treatment with a competing ligand.
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Figure 4.2 Reaction Diagram of the Microkinetic Model (MM)
The membrane acts as depot for salmeterol (Salm) from where it is steadily released. Salo =
Sal outside the cell; Rm = membrane bound β2AR; Sal:Rm = salmeterol bound to β2AR on the
membrane; Isoo = isoproterenol in the aqueous phase; Iso:Rm = isoproterenol bound to β2AR
on the membrane.

114

Table 4.2 Parameters of the Microkinetic Model
Reaction Name

Parameter

Reference/Rationale

Salmeterol association
rate (to plasma
membrane)

kin= 107 min-1

Kp(mem) = 22500 (Rhodes, Newton
et al. 1992)

Salmeterol release rate
(from plasma membrane)

krel = 0.004 min-1

t1/2 ~ 180 min (Rhodes, Newton et
al. 1992; Austin, Barton et al.
2003)

Salmeterol On

kSal on = 8.4e+07 M-1.min-1

Rate of salmeterol binding β2AR
assumed to similar to isoproterenol

Salmeterol Off

kSal off = 0.168 min-1

Kd ~ 2 nM (Rong, Arbabian et al.
1999)

Isoproterenol On

kIso on = 8.4e+07 M-1.min-1

Kf set to achieve ~ 47 msec τ for
10µM isoproterenol binding
(Reiner, Ambrosio et al. 2010)

Isoproterenol Off

kIso off = 235.2 min-1

Kd ~ 283 nM (Vayttaden, Friedman
et al. 2010)
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Figure 4.3 Microkinetic Model – Salmeterol Long Action and Reassertion
Simulations based on Figure 4.2 and Table 4.2. Long Action – Salmeterol bound active β2AR
(black line) persists after 2 min treatment. Reassertion – Salmeterol bound active β2AR
(black line) reappears even after 20 min washout and 20 min isoproterenol treatment followed
by a 20 min second washout.

116

4.2.3. Exosite Model (EM)
The exosite model (Figure 4.4) is characterised by the binding of salmeterol on the
receptor at a site that is by necessity adjacent to the saligenin site. This exosite
binding enables preferable partitioning of salmeterol into the plasma membrane
which then serves as a reservoir for prolonged salmeterol action (Jack 1991). A
key difference between the exosite and microkinetic model is that in the
microkinetic model partitioning of salmeterol into the plasma membrane is driven
by the drug’s lipophilicity whereas in the exosite model it is dependent upon the
receptor concentration.
Table 4.3 lists the parameters used in my representation of the exosite model.
Figure 4.5 shows that this representation of the exosite model can recapitulate both
long action and reassertion of salmeterol post treatment with a competing ligand.
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Figure 4.4 Reaction Diagram of the Exosite Model (EM)
The β2AR has an exosite to which salmeterol is bound and retained in the membrane. The
subscript m denotes that the species is retained on the plasma membrane and the subscript o
denotes that the species is in the aqueous phase. R denotes the β2AR and it is followed by
subscripts eam, EAm, Eam and eAm where e/E and a/A denote the exosite and active site
respectively and the case denotes whether these sites are empty or occupied. A lower case
denotes that the site is empty and an upper case denotes that the site is occupied. Thus Ream
= β2AR with empty active- and exo-sites; Sal:REAm = Salmeterol bound to both active- and
exo-site on the β2AR; Sal:REam = Salmeterol bound to only exo-site on the β2AR; Sal:ReAm =
Salmeterol bound to only active-site on the β2AR; Iso:ReAm = Isoproterenol bound to activesite on the β2AR; Sal:Iso:ReAm = Isoproterenol bound to active-site on the β2AR. Reactions 6
and 7 are ignored in the simulations since at longer treatments active site should be occupied
and exosite should be quasi-irreversibly occupied.
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Table 4.3 Parameters of the Exosite Model
Reaction Name

Parameter

Reference/Rationale

Salmeterol association
rate (to β2AR exosite)

kin= 8e+07 M .min

Set to match τ (at 4e-07 M
salmeterol and 3e-07 M naïve
β2AR) for membrane association
of salmeterol in microkinetic model

Salmeterol release rate
(from β2AR exosite)

kexo = 0.004 min-1

t1/2 ~ 180 min (Rhodes, Newton et
al. 1992; Austin, Barton et al.
2003)

Salmeterol On
(to β2AR active site)

kSal on = 20 min-1

Set to match τ (at 4e-07 M
salmeterol and 3e-07 M naïve
β2AR) for salmeterol binding β2AR
in microkinetic model

Salmeterol Off
(from β2AR active site)

kSal off = 0.168 min-1

Kd ~ 2 nM (Rong, Arbabian et al.
1999)

Isoproterenol On

kIso on = 8.4e+07 M-1.min-1

Kf set to achieve ~ 47 msec τ for
10µM isoproterenol binding
(Reiner, Ambrosio et al. 2010)

Isoproterenol Off

kIso off = 235.2 min-1

Kd ~ 283 nM (Vayttaden, Friedman
et al. 2010)

-1

-1
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Figure 4.5 Exosite Model – Salmeterol Long Action and Reassertion
Simulations based on Figure 4.4 and Table 4.2. Long Action – Salmeterol bound active β2AR
(black line) persists after 2 min treatment. Reassertion – Salmeterol bound active β2AR
(black line) reappears even after 20 min washout and 20 min isoproterenol treatment.
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4.2.4. Combined Model (CM)
The third model proposed for salmeterol action was the rebinding model (Szczuka,
Wennerberg et al. 2009). This model explains long action of salmeterol by rapid
rebinding of the released salmeterol to an adjacent receptor. As recognised by the
proponents of this model, rebinding cannot by itself explain reassertion properties
of salmeterol when a competing ligand is present. It is now generally accepted that
the properties of salmeterol are due to a combination of microkinetics, exosite
binding to the receptor and rebinding. I have thus made a composite model that
allows for all three events to occur. The combined model is shown in Figure 4.6
and its ability to capture long action and reassertion properties of salmeterol is
shown in Figure 4.7. Table 4.4 lists the parameters used in my representation of
the combined model.
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Figure 4.6 Reaction Diagram of the Combined Model (CM)
The β2AR has an exosite to which salmeterol is bound and retained in the membrane. The
membrane also acts as depot for salmeterol (Salm) from where it is steadily released. R
denotes the β2AR and it is followed by subscripts eam, EAm, Eam and eAm where e/E and
a/A denote the exosite and active site respectively and the case denotes whether these sites
are empty or occupied. A lower case denotes that the site is empty and an upper case denotes
that the site is occupied. Thus Ream = β2AR with empty active- and exo-sites; Sal:REAm =
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Salmeterol bound to both active- and exo-site on the β2AR; Sal:REam = Salmeterol bound to
only exo-site on the β2AR; Sal:ReAm = Salmeterol bound to only active-site on the β2AR;
Iso:ReAm = Isoproterenol bound to active-site on the β2AR; Sal:Iso:ReAm = Isoproterenol
bound to active-site on the β2AR. Reactions 9 - 11 are ignored in the simulations since at
longer treatments active site should be occupied and salmeterol exosite binding is quasiirreversible. Isoo = isoproterenol in the aqueous phase
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Table 4.4 Parameters of the Combined Model
Reaction Name

Parameter

Reference/Rationale

Salmeterol association
rate (to β2AR exosite)

kin’ = 8e+07 M-1.min-1

Set to match τ (at 4e-07 M
salmeterol and 3e-07 M naïve
β2AR) for membrane association
of salmeterol in microkinetic model

Salmeterol association
rate (to plasma
membrane)

kin= 107 min-1

Kp(mem) = 22500 (Rhodes, Newton
et al. 1992)

Salmeterol release rate
(from β2AR exosite or
from plasma membrane)

kexo = krel = 0.004 min-1

t1/2 ~ 180 min (Rhodes, Newton et
al. 1992; Austin, Barton et al.
2003)

Salmeterol On (to β2AR
active site)

kSal on’ = 20 min

Set to match τ (at 4e-07 M
salmeterol and 3e-07 M naïve
β2AR) for salmeterol binding β2AR
in microkinetic model (see below)

Salmeterol On (to β2AR
active site)

kSal on = 8.4e+07 M-1.min-1

Rate of salmeterol binding β2AR
assumed to similar to isoproterenol

Salmeterol Off
(from β2AR active site)

kSal off = 0.168 min-1

Kd ~ 2 nM (Rong, Arbabian et al.
1999)

Isoproterenol On

kIso on = 8.4e+07 M-1.min-1

Kf set to achieve ~ 50 msec τ for
10µM isoproterenol binding
(Reiner, Ambrosio et al. 2010)

Isoproterenol Off

kIso off = 235.2 min-1

Kd ~ 283 nM (Vayttaden, Friedman
et al. 2010)

-1
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Figure 4.7 Combined Model – Salmeterol Long Action and Reassertion
Simulations based on Figure 4.6 and Table 4.4. Long Action – Salmeterol bound active β2AR
(black line) persists after 2 min treatment. Reassertion – Salmeterol bound active β2AR
(black line) reappears even after 20 min washout and 20 min isoproterenol treatment.

125

4.2.5. Salmeterol β2AR Binding Models Coupled to the GRK Model
Since all the three salmeterol models presented thus far in Section 4.2 deal only
with events at the receptor ligand interaction level it is necessary to follow up these
models to see if the simulated behaviour of salmeterol action holds true when
downstream signalling events are introduced. Towards that end I created three
new models (Figure 4.8, Models 8-10) that looked at the effects of coupling GRKmediated β2AR regulation to the existing models (MM/EM/CM). Since the
Combined Model coupled to the GRK model encompasses both exosite and
microkinetics I have discussed only that variation of the model in detail below. The
exosite model and the microkinetic model coupled by itself to the GRK model
showed similar results (data not shown).
To validate these phenomenological models I simulated isoproterenol- and
salmeterol-induced GRK-mediated β2AR phosphorylation at saturating agonist
concentrations. All three models (8-10) have a general match to the
phosphorylation kinetics. Figure 4.9 shows results from only the combined model.
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Figure 4.8 Reaction Diagram of the MM/EM/CM Coupled to GRK-Mediated β2AR
Regulation
L is ligand (salmeterol/isoproterenol); the blue box with the letterings MM/EM/CM denotes the
microkinetic, exosite and combined models for ligand receptor interactions presented above;
Reaction numbers are as described in Table 3.1 (c.f. Chapter 3). Isoo = isoproterenol outside
the cell; Salo = salmeterol outside the cell, Arr = arrestin; surface species are denoted with a
subscript s; internalised species are denoted with a subscript i, GRK phosphorylated species
are denoted with a subscript g.
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Figure 4.9 Simulated Time Course of GRK Site Phosphorylation
Simulations of GRK phosphorylation on treatment with 10
10µM
M epinephrine (brown lines) or
0.4µM
M salmeterol (orange lines) in the Combined-GRK
GRK (Model 10) model. The experimental
expe
results are shown as discrete points.
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These validated models were then tested for salmeterol properties of long action
and reassertion. All three models show reassertion capabilities but none of them
were now able to show considerable long action. Figure 4.10A shows the results
for the Combined-GRK model. This can be explained by the simulated rapid
arrestin binding to the ligand bound phosphorylated β2AR as measured for
isoproterenol (Krasel, Bunemann et al. 2005). In the absence of information to the
contrary I had assumed that salmeterol-induced recruitment of arrestin would be as
rapid as isoproterenol-induced arrestin recruitment. When I now used the
Combined-GRK model to simulate salmeterol induced receptor internalisation
(Figure 4.10B) I see that arrestin affinity for the salmeterol-bound receptor had to
be reduced 100 fold to match experimentally measured salmeterol-induced
receptor internalisation.
We had previously shown that contrary to isoproterenol behaviour, there is
negligible β2AR internalisation on treating with saturating salmeterol
concentrations. This negligible salmeterol-induced internalisation can be rescued
by overexpression of arrestin without affecting internalisation induced by other
agonists (Moore, Millman et al. 2007). I had previously shown that a 100-fold
reduction in arrestin affinity for salmeterol/β2AR complex was needed to simulate
the negligible internalisation, and this did not affect the simulated phosphorylation
kinetics (Vayttaden, Friedman et al. 2010). This supports our idea that salmeterol
stabilises an alternate conformation of the receptor where eventually the GRK
phosphorylation matches the levels attained by full agonists but arrestin affinity of
the salmeterol/β2AR complex is markedly reduced. In the light of this I modified
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models 8-10 by a ten-fold reduction of arrestin on rate and a ten-fold increase of
arrestin on rate to salmeterol/β2AR complex. These modified models were all able
to now recapitulate both long action and reassertion effects of salmeterol. Figure
4.10C shows the results of only the Combined-GRK model with the abrogation of
internalisation.
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Figure 4.10 Simulated Salmeterol Long Action, Reassertion and SalmeterolInduced Internalisation
Simulations based on Figure 4.8 and Tables 2.1and 4.1-3. Long Action – Salmeterol bound
active β2AR (black line) persists after 2 min treatment only in C. Reassertion – Salmeterol
bound active β2AR (black line) reappears even after 20 min washout and 20 min in A and C.
(A) Combined-GRK models with default arrestin kinetics; (B) Sal-induced internalisation, with
varying arrestin kinetics and (C) Combined-GRK model with 100 fold lower arrestin affinity for
salmeterol/ β2AR complex with internalisation inhibited.
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In summary, all existing models of salmeterol action deal solely with receptor ligand
events. When we consider downstream signalling events none of these models can
effectively explain salmeterol long action. It becomes necessary to invoke reduced
arrestin affinity for the salmeterol/β2AR complex in order to simulate experimentally
measured salmeterol-induced β2AR internalisation (Vayttaden, Friedman et al.
2010) and to rescue loss of long action (Section 4.2 of this thesis).
4.3. Model Limitations
For ease of comparison of microkinetic and exosite models on the same time
scales I assumed that the two mechanisms have the same rates even though we
know that the t1/2 for salmeterol release from synthetic membranes is ~ 3 hrs
(Rhodes, Newton et al. 1992) and for exosite binding is possibly 2-3 fold longer. In
spite of these assumptions the models described herein can be used to provide
important proof-of-concept simulations about the necessity of reduced arrestin
affinity for salmeterol bound β2AR complex.
Figure 4.11 shows experimental measures of cyclic AMP on both short term (30
mins) and long term (12 hrs) treatment with salmeterol in the presence of IBMX to
inhibit PDE activity. The experimental data clearly shows that in spite of lower
coupling efficiency of salmeterol activated β2AR it is still able to activate significant
amount of adenylyl cyclases to show measureable cAMP in the presence of PDE
inhibitors. Inspite of the use of IBMX the PDE inhibition is not complete, so by 30
minutes we see a drop in cAMP levels in human airways smooth muscle (HASM)
cells treated with saturating isoproterenol (Figure 4.11B). Our data also shows that
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a 12 hour pre-treatment with salmeterol does bring about significant desensitisation
of the cAMP synthesis machinery. My models of salmeterol action encompass only
the G-protein independent GRK-mediated β2AR regulation and so cannot explain
the experimental measurements shown in Figure 4.11. From my simulations
(Section 4.2 of this thesis) and our experimental data (Moore, Millman et al. 2007)
it is clear that the GRK-mediated β2AR regulation does not bring about significant
receptor desensitisation on account of weak arrestin affinity so the reduction in
cAMP synthesis seen in Figure 4.11B is due to other parts of the signaling
machinery. Therefore to better capture the dynamics of salmeterol-induced β2AR
desensitisation it is necessary to include PKA- and PDE-mediated regulatory
components in the model.
Since salmeterol association and dissociation kinetics from both the active- and
exo-site are difficult to measure it is necessary to do a thorough analysis on the
effects of variations in these rates on the simulated properties of salmeterol long
action and reassertion in models 8-10, although only varying the exosite release is
of real consequence over the long treatment periods since we could get good
measures of active site on/off from the Kd. Also it would be necessary to include
salmeterol dissociation from the GRK phosphorylated β2AR species with or without
arrestin so that dephosphorylation and recycling experiments can be simulated.
This would have predictive value on account of the difficulties in washing out
salmeterol in an experiment. In the next chapter I show very preliminary work
towards creating a model that is aimed at explaining the effects of GRK-/PKA/Arrestin-/PDE-mediated regulation of β2AR signaling.
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Figure 4.11 cAMP Measured in HASMs in Response to Salmeterol and
Isoproterenol Treatment*
(A) cAMP measured in response to 1 µM Isoproterenol or 50 nM Salmeterol treatment for 30
minutes when the cells have been pre-treated with IBMX for 30 mins to inhibit PDE activity. (B)
cAMP measured in response to 100 µM Isoproterenol treatment ± 12 hour pre-treatment with
20 nM Salmeterol. Sal-induced internalisation, with varying arrestin kinetics and (C)
Combined-GRK model with100 fold lower arrestin affinity for salmeterol/ β2AR complex.
*

Experiments performed by Ms.Jacqueline Friedman
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5. Unified Model for PKA-/PDE-/GRK-Mediated Regulation of β2AR
Signalling
This chapter presents preliminary work towards combining models from
“Quantitative Modeling of GRK-Mediated β2AR Regulation.” Vayttaden SJ, Friedman
J, Tran TM, Rich TC, Dessauer CW, Clark RB (2010) PLoS Comput Biol 6(1):
e1000647. doi:10.1371/journal.pcbi.1000647and “Roles of GRK and PDE4 activities in
the regulation of beta2 adrenergic signaling” Xin W, Tran TM, Richter W, Clark RB,
Rich TC J Gen Physiol. 2008 Apr;131(4):349-64.
My work presented in Chapter 4 suggests that arrestin-mediated desensitisation
cannot be the major mode of desensitisation for partial agonists like salmeterol. My
work presented in Chapter 3 shows that the rapid arrestin-mediated desensitisation
with transient levels of high concentrations of a full agonist like isoproterenol is fully
reversible on washout of the agonists and that there is increased desensitisation on
repeated agonist delivery inspite of near complete resensitisation during washouts. To
understand the effects of prolonged salmeterol maintenance treatment and
isoproterenol rescue treatment and to identify the dominant β2AR desensitisation
pathways under these different therapeutic regimens it then becomes necessary to
follow PKA-/PDE-/GRK-/Arrestin-mediated regulation of β2AR signaling in HASMs.
Due to the low receptor number of HASMs the measure of GRK- and PKA-mediated
β2AR phosphorylation and β2AR internalisation in HASMs is inherently noisy. These
measurements can be made in our stable β2AR overexpressions in HEK293 cells. It is
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possible to measure cAMP profiles in HASMs in response to treatment with various βagonists in the presence or absence of PDE inhibitors. The use of PDE inhibitors is not
without difficulties in that inhibitors like IBMX do not completely inhibit all PDE activity
in the cells (Figure 5.1). In our stable β2AR overexpressions in HEK293s the basal
PDE activity is up regulated to compensate for the β2AR overexpression. Thus due to
the difficulties in obtaining experimental readouts of PKA-/PDE-/GRK-/Arrestin
signaling modules in β2AR regulation in a single cell line, it becomes necessary to
pool experimental data from both HASMs and stable β2AR overexpressions in
HEK293s.
A mathematical representation of the β2AR regulation involving PKA-/PDE-/GRK/Arrestin signaling modules working together in a single model can then be used to
simulate the behaviour of the modules for which data is missing in either HEKs or
HASMs. The individual signalling modules of the model can be validated against
appropriate data sets while varying receptor number in the model depending on
whether HASM data or HEK293 data is being used. This combination of experiments
across different cell lines and modeling is expected to yield insight into which of the
signalling modules plays a major role in β2AR desensitisation during various treatment
regimens.
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Figure 5.1 cAMP in Response to Isoproterenol Treatment.*
cAMP measured in response to 1 µM isoproterenol ± IBMX pretreatment for 30 mins to inhibit
PDE activity. At 10 mins post isoproterenol treatment 0.1 µM propranolol is added to displace
isoproterenol and abrogate β2AR activated adenylyl cyclase activity. If IBMX inhibition of
PDEs were 100% then the cAM levels post propranolol treatment wouldn’t have deacayed
significantly.
*

Experiments performed by Ms.Jacqueline Friedman in HASMs.

137

Some of the weaknesses of this approach are; 1) there will always be unknown
variability from one cell line to the other, this will make creating a unique model to
explain all datasets very challenging; 2) the number of species and reactions in this
model will be higher than any of the previously discussed models which could result in
longer computation times; 3) there will also be an increase in unknown parameter
values which will require parameter estimation; 4) the large model size will require
multiple iterations of the model building exercise before we can settle on the simplest
model that can simulate the behavior of all the signalling modules that we are
interested in. To create a consensus model I combined my model of the GRK/Arrestin
modules (Vayttaden, Friedman et al. 2010) with that of the PKA/PDE modules that our
group had published previously (Xin, Tran et al. 2008). The reaction diagram for the
unified model as it pertains to experimental measurements of agonist-induced GRKmediated β2AR-phosphorylation, PKA-mediated β2AR-phosphorylation, β2ARdephosphorylation, -trafficking, -desensitisation, -resensitisation and -cAMP profile is
given in Figures 5.2-5.5 and Table 5.1 lists its parameters.
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Figure 5.2 Reaction Diagram of β2AR Level Regulation at the Plasma Membrane.
This reaction diagram describes the β2AR level regulation modules at the plasma membrane
as highlighted in red in the inset. L is ligand; β2AR* is active state of β2AR; β2ARg is GRKphosphorylated β2AR; β2ARp is PKA-phosphorylated β2AR; Arr is arrestin; C is catalytic
subunit of PKA. The reaction numbers in green correspond to rate constants described in
Table 5.1.
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Figure 5.3 Reaction Diagram of Gs/PKA/PDE Activation Modules in β2AR
Regulation.
This reaction diagram describes the Gs/PKA/PDE activation modules in β2AR regulation at the
plasma membrane as highlighted in red in the inset. Gs is G protein αs; null indicates an
implicit substrate or product; R is the regulatory subunit of PKA; C is catalytic subunit of PKA;
PDEp indicates PKA phosphorylated PDE. The reaction numbers in green correspond to rate
constants described in Table 5.1.
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Figure 5.4 Reaction Diagram of β2AR-Trafficking and Degradation.
This reaction diagram describes the β2AR-trafficking and degradation modules in β2AR
regulation as highlighted in red in the inset. β2ARi indicates an internalised β2AR; Li indicates
an internalised ligand; null indicates an implicit product; β2AR* is active state of β2AR; β2ARg
is GRK-phosphorylated β2AR; β2ARp is PKA-phosphorylated β2AR; Arr is arrestin. The
reaction numbers in green correspond to rate constants described in Table 5.1.
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Figure 5.5 Reaction Diagram of Post-Internalisation Events in β2AR Regulation.
This reaction diagram describes the post-internalisation events of β2AR regulation as
highlighted in red in the inset. β2ARi indicates an internalised β2AR; Li indicates an
internalised ligand; β2AR* is active state of β2AR; β2ARg is GRK-phosphorylated β2AR;
β2ARp is PKA-phosphorylated β2AR; Arr is arrestin. The reaction numbers in green
correspond to rate constants described in Table 5.1.
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Table 5.1 Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR Regulation
Model
No.

Parameter Name

Value

Reference/Rationale

Fig. No.

1

R1f: β2AR Activation

40 /sec

5.2

2

R1r: β2AR* Inactivation

200 /sec

Rates adjusted to achieve
appropriate levels of basal
active β2AR.

3

R2f: L On β2AR*

14 µM-1.sec-1

4

R2r: L Off L:β2AR*

6.3 sec-1

5

R3f: Gs Activation

Kc = 15 µM;
kact = 15 sec1
; kh = 0.8
sec-1

6

R3r: Gs:GTP Hydrolysis

'( : '*+  -./0 1

Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.2
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).
(Kc) Equilibrium constant for
activated β2AR and Gs; (kact)
Rate constant of Gs activation
by active β2AR; (kh) Rate
constant of GTP hydrolysis
(Xin, Tran et al. 2008).

5.3

23456789 :567;< =2:? 1 '( : '@+⁄A/   -C 1 '( : '*+

Adapted from equations 2, 5 and 6 (Xin, Tran et al. 2008).

7

R4: cAMP Production

ACsyn = 10
µM.sec-1;
KGsAC = 315
µM

(ACsyn) cAMP synthesis rate;
(KGsAC) Equilibrium constant for
Gs:GTP and AC (Xin, Tran et
al. 2008).

5.3

-  :D(EF 1 '( : '*+⁄AG(HI ; Adapted from equation 8 (Xin, Tran et al. 2008).
8

R5f: cAMP On R2:C2

9

0.4 µM-1.sec1

(Xin, Tran et al. 2008)

5.3

R5r: cAMP Off
cAMP:R2:C2

0.2 sec-1

(Xin, Tran et al. 2008)

5.3

10

R6f: cAMP On
cAMP:R2:C2

0.4 µM-1.sec1

(Xin, Tran et al. 2008)

5.3

11

R6r: cAMP Off
cAMP2:R2:C2

0.2 sec-1

(Xin, Tran et al. 2008)

5.3

12

R7f: cAMP On
cAMP2:R2:C2

5 µM-1.sec-1

(Xin, Tran et al. 2008)

5.3

13

R7r: cAMP Off
cAMP3:R2:C2

1 sec-1

(Xin, Tran et al. 2008)

5.3

14

R8f: cAMP On
cAMP3:R2:C2

5 µM-1.sec-1

(Xin, Tran et al. 2008)

5.3
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR
Regulation Model
No.

Parameter Name

Value

Reference/Rationale

Fig. No.

15

R8r: cAMP Off
cAMP4:R2:C2

1 sec-1

(Xin, Tran et al. 2008)

5.3

16

R9f: 2C Off cAMP4:R2:C2

70 sec-1

(Xin, Tran et al. 2008)

5.3

17

R9r: 2C On cAMP4:R2

0.75 µM2
.sec-1

(Xin, Tran et al. 2008)

5.3

18

R10f: PKA
Phosphorylation β2AR

(Tran, Friedman et al. 2004)

5.2

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

(Tran, Friedman et al. 2004)

5.2

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

Rates adjusted to achieve
appropriate levels of basal
active β2AR.

5.2

19

R10r: PKA
Dephosphorylation β2ARp

20

R11f: PKA
Phosphorylation β2AR*

[Fraction
Active
PKA]*83 sec1

0.036 sec-1

[Fraction
Active
PKA]*83 sec1

21

R11r: PKA
Dephosphorylation
β2AR*p

0.036 sec

22

R12f: β2ARp Activation

40 /sec

23

R12r: β2AR*p Inactivation

200 /sec

24

R13f: L On β2AR*

14 µM-1.sec-1

25

R13r: L Off L:β2AR*

6.3 sec-1

26

R14f: PKA
Phosphorylation L:β2AR*

[Fraction
Active
PKA]*83 sec-

-1

Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.2
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).

(Tran, Friedman et al. 2004)

5.2

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

1

27

R14r: PKA
Dephosphorylation
L:β2AR*p

0.036 sec

-1
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR
Regulation Model
No.

Parameter Name

Value

Reference/Rationale

Fig. No.

28

R15f: PKA
Phosphorylation PDE

[Fraction
Active
PKA]*0.015
sec-1

Rates need to be adjusted for
my system (Xin, Tran et al.
2008)

5.3

29

R15r: PKA
Dephosphorylation PDEp

0.005 sec-1

Rates need to be adjusted for
my system (Xin, Tran et al.
2008)

5.3

R16: PDE Activity

kPDE =0.15
µM.sec-1;
kPDEp =2.5 X (
kPDE); I
=Appropriate
PDE inhibitor
(Xin, Tran et al. 2008)
concentration
as used in
experiment ;
KI=0.1 µM
(for
Rolipram)

30

-

J



+@K 1 5:L+ 1 -MNO

+@KX  1 5:L+ 1 -MNOX

T
VW 5:L+
AU
Adapted from equation 9 (Xin, Tran et al. 2008).
5:L+

PAQ MNO 1 R1

5.3

31

R17f: GRK
Phosphorylation L:β2AR*

32

R17r: GRK
Dephosphorylation
β2AR*g

0.036 sec

33

R18f: GRK
Phosphorylation L:β2AR*p

34

R18r: GRK
Dephosphorylation
L:β2AR*pg

8.4 sec-1

PAQ MNOX 1 R1

T
VW
AU

(Tran, Friedman et al. 2004)

5.2

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

8.4 sec-1

(Tran, Friedman et al. 2004)

5.2

0.036 sec-1

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

-1
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Regulation Model
No.

Parameter Name

Value

35

R19f: PKA
Phosphorylation L:β2AR*g

[Fraction
Active
PKA]*83 sec-

Reference/Rationale

Fig. No.

(Tran, Friedman et al. 2004)

5.2

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

1

36

R19r: PKA
Dephosphorylation
L:β2AR*pg

0.036 sec

37

R20f: Arrestin On
L:β2AR*g

1620 sec-1

Rate of arrestin binding = 26.6
± 5.9 /min (Krasel, Bunemann
et al. 2005)

5.2

38

R20r: Arrestin Off
Arr:L:β2AR*g

240 sec-1

Rate of arrestin dissociation
assumed to match measured
Kd.

5.2

39

R21f: Arrestin On
L:β2AR*pg

1620 sec-1

Rate of arrestin binding = 26.6
± 5.9 /min (Krasel, Bunemann
et al. 2005)

5.2

40

R21r: Arrestin Off
Arr:L:β2AR*pg

240 sec

Rate of arrestin dissociation
assumed to match measured
Kd.

5.2

41

R22f: L On Arr:β2AR*g

14 µM-1.sec-1

42

R22r: L Off Arr:L:β2AR*g

6.3 sec-1

43

R23f: L On Arr:β2AR*pg

14 µM-1.sec-1

44

R23r: L Off Arr:L:β2AR*pg

6.3 sec-1

45

R24: Arrestin Off Arr:
β2AR*g

660 sec-1

Rate of arrestin dissociation =
10.86 ± 1.2 /min (Krasel,
Bunemann et al. 2005).

5.2

46

R25: Arrestin Off Arr:
β2AR*pg

660 sec-1

Rate of arrestin dissociation =
10.86 ± 1.2 /min (Krasel,
Bunemann et al. 2005).

5.2

-1

-1

Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.2
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).
Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.2
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).
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No.

Parameter Name

Value

Reference/Rationale

Fig. No.

47

R26f: Arr:β2ARg Activation

40 /sec

R26r: Arr:β2AR*g
Inactivation

5.2

48

200 /sec

Rates adjusted to achieve
appropriate levels of basal
active β2AR.

49

R27f: Arr:β2ARpg
Activation

40 /sec

5.2

50

R27r: Arr:β2AR*pg
Inactivation

200 /sec

Rates adjusted to achieve
appropriate levels of basal
active β2AR.

51

R28: Arrestin Off Arr:
β2AR*g

660 sec-1

Rate of arrestin dissociation =
10.86 ± 1.2 /min (Krasel,
Bunemann et al. 2005).

5.2

52

R29: Arrestin Off Arr:
β2AR*pg

660 sec-1

Rate of arrestin dissociation =
10.86 ± 1.2 /min (Krasel,
Bunemann et al. 2005).

5.2

53

R30f: PKA
Phosphorylation β2ARg

(Tran, Friedman et al. 2004)

5.2

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

Rates adjusted to achieve
appropriate levels of basal
active β2AR.

5.2

Rates adjusted to achieve
appropriate levels of basal
active β2AR.

5.2

(Tran, Friedman et al. 2004)

5.2

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

[Fraction
Active
PKA]*83 sec1

54

R30r: PKA
Dephosphorylation
β2ARpg

0.036 sec

55

R31f: β2ARg Activation

40 /sec

56

R31r: β2AR*g Inactivation

200 /sec

57

R32f: β2ARpg Activation

40 /sec

58

R32r: β2AR*pg
Inactivation

200 /sec

59

R33f: PKA
Phosphorylation β2AR*g

60

R33r: PKA
Dephosphorylation
β2AR*pg

-1

[Fraction
Active
PKA]*83 sec1

0.036 sec

-1
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No.

Parameter Name

61

R34: GRK
Dephosphorylation β2ARg

62

R35: GRK
Dephosphorylation
β2ARpg

63

R36: GRK
Dephosphorylation β2ARg

Value

Reference/Rationale

Fig. No.

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

0.036 sec-1

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

64

R37: GRK
Dephosphorylation
β2ARpg

0.036 sec-1

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

65

R38f: L On β2AR*g

14 µM-1.sec-1

66

R38r: L Off L:β2AR*g

6.3 sec-1

67

R39f: L On β2AR*pg

14 µM-1.sec-1

68

R39r: L Off L:β2AR*pg

6.3 sec-1

69

R40f: β2AR Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

70

R40r: β2ARi Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

71

R41f: β2ARg Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

72

R41r: β2ARgi Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

73

R42f: β2ARp Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

0.036 sec

-1

0.036 sec

-1

Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.2
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).
Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.2
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).
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Parameter Name

Value

Reference/Rationale

Fig. No.

74

R42r: β2ARpi Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

75

R43f: β2ARpg Basal
Internalisation

0.51 sec

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

76

R43r: β2ARpgi Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

77

R44f: β2AR* Basal
Internalisation

0.51 sec

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

78

R44r: β2AR*i Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

79

R45f: β2AR*g Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

80

R45r: β2AR*gi Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

81

R46f: β2AR*p Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

82

R46r: β2AR*pi Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

83

R47f: β2AR*pg Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

84

R47r: β2AR*pgi Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

85

R48f: L:β2AR* Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

86

R48r: L:β2AR*i Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

-1

-1
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Parameter Name

Value

Reference/Rationale

Fig. No.

87

R49f: L:β2AR*g Basal
Internalisation

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

0.51 sec

5.4

88

R49r: L:β2AR*gi Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

89

R50f: L:β2AR*p Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

90

R50r: L:β2AR*pi Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

91

R51f: L:β2AR*pg Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

92

R51r: L:β2AR*pgi
Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

93

R52f: Arr:β2ARg Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

94

R52r: Arr:β2ARgi
Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

95

R53f: Arr:β2ARpg Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

96

R53r: Arr:β2ARpgi
Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

97

R54f: Arr:β2AR*g Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

98

R54r: Arr:β2AR*gi
Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

99

R55f: Arr:β2AR*pg Basal
Internalisation

0.51 sec-1

Rates used to match negligible
basal internalisation (Morrison,
Moore et al. 1996).

5.4

-1
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100

R55r: Arr:β2AR*pgi
Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

101

R56f: Arr:L:β2AR*g
Internalisation

13.2 sec-1

kf = 0.22 /min (Tran, Friedman
et al. 2004).

5.4

102

R56r: Arr:L:β2AR*gi
Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

103

R57f: Arr:L:β2AR*pg
Internalisation

13.2 sec-1

kf = 0.22 /min (Tran, Friedman
et al. 2004).

5.4

104

R57r: Arr:L:β2AR*pgi
Recycling

5.4 sec-1

kf = 0.09 /min (Tran, Friedman
et al. 2004).

5.4

5.4

105

R58: Li Degradation

100 sec-1

Catecholamine group should
degrade rapidly. Arbitrarily set
high to prevent persistent
ligand rebinding post
internalisation

106

R59: β2ARi Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

107

R60: β2ARgi Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

108

R61: β2ARpi Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

109

R62: β2ARpgi Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

110

R63: β2AR*i Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

111

R64: β2AR*gi Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

112

R65: β2AR*pi Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

113

R66: β2AR*pgi
Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

114

R67: L:β2AR*i
Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4
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115

R68: L:β2AR*gi
Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

116

R69: L:β2AR*pi
Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

117

R70: L:β2AR*pgi
Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

118

R71: Arr:β2ARgi
Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

119

R72: Arr:β2ARpgi
Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

120

R73: Arr:β2AR*gi
Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

121

R74: Arr:β2AR*pgi
Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

122

R75: Arr:L:β2AR*gi
Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

123

R76: Arr:L:β2AR*pgi
Degradation

0.24 sec-1

t1/2 = 3-4 hours (Liang, Hoang
et al. 2008)

5.4

124

R77f: β2ARi Activation

40 /sec

5.5

125

R77r: β2AR*i Inactivation

200 /sec

Rates adjusted to achieve
appropriate levels of basal
active β2AR.

126

R78f: L On β2AR*i

14 µM-1.sec-1

127

R78r: L Off L:β2AR*i

6.3 sec-1

128

R79: GRK
Dephosphorylation
L:β2AR*gi

129

R80f: Arrestin On
L:β2AR*gi

Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.5
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).

0.036 sec-1

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.5

1620 sec-1

Rate of arrestin binding = 26.6
± 5.9 /min (Krasel, Bunemann
et al. 2005)

5.5
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130

R80r: Arrestin Off
Arr:L:β2AR*gi

240 sec

131

R81f: L On Arr:β2AR*gi

14 µM-1.sec-1

132

R81r: L Off Arr:L:β2AR*gi

6.3 sec-1

133

R82f: Arr:β2ARgi
Activation

40 /sec

134

R82r: Arr:β2AR*gi
Inactivation

200 /sec

135

R83: Arrestin Off
Arr:β2ARgi

136

-1

Reference/Rationale

Fig. No.

Rate of arrestin dissociation
assumed to match measured
Kd.

5.5

Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.5
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).
Rates adjusted to achieve
appropriate levels of basal
active β2AR.

5.5

660 sec-1

Rate of arrestin dissociation =
10.86 ± 1.2 /min (Krasel,
Bunemann et al. 2005).

5.5

R84: Arrestin Off
Arr:β2AR*gi

660 sec-1

Rate of arrestin dissociation =
10.86 ± 1.2 /min (Krasel,
Bunemann et al. 2005).

5.5

137

R85f: L On β2AR*gi

14 µM-1.sec-1

138

R85r: L Off L:β2AR*gi

6.3 sec-1

139

R86f: β2ARi Activation

40 /sec

140

R86r: β2AR*i Inactivation

200 /sec

141

R87: GRK
Dephosphorylation β2ARgi

142

R88: GRK
Dephosphorylation
β2AR*gi

0.036 sec

143

R89f: β2ARpi Activation

40 /sec

144

R89r: β2AR*pi Inactivation

200 /sec

0.036 sec-1

-1

Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.5
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).
Rates adjusted to achieve
appropriate levels of basal
active β2AR.

5.5

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.5

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.5

Rates adjusted to achieve
appropriate levels of basal
active β2AR.

5.5
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145

R90f: L On β2AR*pi

14 µM-1.sec-1

146

R90r: L Off L:β2AR*pi

6.3 sec-1

Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.5
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).

147

R91: GRK
Dephosphorylation
L:β2AR*pgi

0.036 sec

148

R92f: Arrestin On
L:β2AR*pgi

149

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.5

1620 sec-1

Rate of arrestin binding = 26.6
± 5.9 /min (Krasel, Bunemann
et al. 2005)

5.5

R92r: Arrestin Off
Arr:L:β2AR*pgi

240 sec-1

Rate of arrestin dissociation
assumed to match measured
Kd.

5.5

150

R93f: L On Arr:β2AR*pgi

14 µM-1.sec-1

151

R93r: L Off Arr:L:β2AR*pgi

6.3 sec-1

152

R94f: Arr:β2ARpgi
Activation

40 /sec

153

R94r: Arr:β2AR*pgi
Inactivation

154

R95: Arrestin Off Arr:
β2ARpgi

660 sec

155

R96: Arrestin Off Arr:
β2AR*pgi

660 sec-1

156

R97f: L On β2AR*pgi

14 µM-1.sec-1

157

R97r: L Off L:β2AR*pgi

6.3 sec-1

158

R98f: β2ARpgi Activation

40 /sec

159

R98r: β2AR*pgi
Inactivation

200 /sec

-1

200 /sec

-1

Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.5
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).
Rates adjusted to achieve
appropriate levels of basal
active β2AR.

5.5

Rate of arrestin dissociation =
10.86 ± 1.2 /min (Krasel,
Bunemann et al. 2005).

5.2

Rate of arrestin dissociation =
10.86 ± 1.2 /min (Krasel,
Bunemann et al. 2005).

5.2

Rates adjusted to achieve
appropriate τ (Reiner, Ambrosio
5.5
et al. 2010) and Kds (Vayttaden,
Friedman et al. 2010).
Rates adjusted to achieve
appropriate levels of basal
active β2AR.

5.5
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160

R99: GRK
Dephosphorylation
β2ARpgi

161

R100: GRK
Dephosphorylation
β2AR*pgi

162

R101: PKA
Dephosphorylation
β2ARpgi

163

R102: PKA
Dephosphorylation β2ARpi

164

R103: PKA
Dephosphorylation
β2AR*pi

165

R104: PKA
Dephosphorylation
β2AR*pgi

166

R105: PKA
Dephosphorylation
L:β2AR*pi

167

R106: PKA
Dephosphorylation
L:β2AR*pgi

Value

Reference/Rationale

Fig. No.

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.5

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.5

0.036 sec-1

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

0.036 sec-1

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

0.036 sec-1

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

0.036 sec-1

Phosphorylated receptor t1/2 =
18 min (Tran, Friedman et al.
2004; Tran, Friedman et al.
2007)

5.2

0.036 sec

-1

0.036 sec

-1

0.036 sec

-1

0.036 sec

-1
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Table 5.1 (contd.) Parameters for the Unified PKA-/GRK-/PDE-Mediated β2AR
Regulation Model
No.

Parameter Name

Value

Reference/Rationale

Fig. No.
5.2

168

β2ARt=0; HASMs

1µM

Arbitrarily set (Xin, Tran et al.
2008). Need to lower to
0.003µM per my calculations

169

β2ARt=0; HEK293s (over expression)

100µM

Arbitrarily set (Xin, Tran et al.
2008). Need to lower to 0.3µM
per my calculations

5.2

1µM

Arbitrarily set (Xin, Tran et al.
2008).

5.3

1µM

(Xin, Tran et al. 2008).

5.3

4µM

(Xin, Tran et al. 2008).

5.3

170

PDEt=0; HASMs / HEK293s (over
expression)

171

R2:C2t=0; HASMs / HEK293s (over
expression)

172

Gs:GDPt=0; HASMs / HEK293s (over
expression)
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5.1. Assumptions
5.1.1. Receptor Activation
I assumed a ligand-induced stabilisation model for β2AR activation. Here β2AR
denotes the inactive receptor on the plasma membrane, β2AR* the
spontaneously active receptor and L:β2AR, the agonist-induced stable active
receptor. This was done to accommodate the differences in basal activity with
varying receptor levels. The limitations of the two-state model are that it cannot
account for ligand induced differential signalling or bias wherein a wide
spectrum of receptor conformations is stabilised by different agonists to varying
extents and thereby capable of differential signalling.
5.1.2. Ligand On/Off
The ligand binding rates were set in COPASI (COmplex PAthway SImulator)
(Hoops, Sahle et al. 2006) to achieve appropriate t1/2 of 47 msec for 10 µM
epinephrine (Reiner, Ambrosio et al. 2010). Since we had an estimate of Kd for
epinephrine to be ~ 450 nM (Vayttaden, Friedman et al. 2010) the off-rates
were calculated to give the appropriate Kd. The on-rates of isoproterenol were
assumed to be similar to epinephrine and then using a Kd of ~ 283 nM
(Vayttaden, Friedman et al. 2010) appropriate off-rates were calculated.
5.1.3. Receptor Activity
In the current version of the model I have assumed only two receptor states –
active or inactive. Contrary to the GRK-mediated β2AR regulation model
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presented in chapter 3, I haven’t considered intermediate receptor activity levels
dependent on phosphorylation status. In its current version the model will not be
able to capture the effects of PKA phosphorylation of the β2AR on
desensitisation. This simplification was done to reduce the complexity of the
model to capture first the effects of PKA-mediated PDE activation on treatment
with 1 – 100 µM isoproterenol (c.f. Figure 4.11) since at these concentrations
PKA phosphorylation of the β2AR would be saturated (Tran, Friedman et al.
2004). The effects of phosphorylation dependent variable receptor activity will
have to be explored in later versions of the model. I also assume that arrestin
binding and/or internalisation completely uncouples the receptor from Gαs and
therefore these species have no activity.
5.1.4. β2AR-Phosphorylation Kinetics
In my model the rate of PKA phosphorylation is dependent on [C] which is the
fraction of activated PKA. We’ve measured 0.01 – 100 nM epinephrine-induced
PKA-mediated β2AR phosphorylation t1/2 to ~ range from 1–2/min (Tran,
Friedman et al. 2004). I assume that isoproterenol induced β2AR
phosphorylation rates will be in the same range since epinephrine and
isoproterenol have comparable efficacies.
I assumed that ligand activation of β2AR results in only a single event of GRK
phosphorylation where both serines 355 and 356 are simultaneously
phosphorylated. The anti-phosphosite antibody used in our β2AR
phosphorylation studies detects only dual phosphorylation of serines 355, 356.
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Use of our antibody for studying GRK-mediated β2AR phosphorylation kinetics
has been validated by various groups (Tran, Friedman et al. 2004; Shenoy,
Drake et al. 2006; Violin, Ren et al. 2006; Pontier, Percherancier et al. 2008;
Woo, Wang et al. 2009). The disadvantage of this assumption is that it is no
longer possible to project multi-phosphorylation states of the receptor that could
play a role in receptor sorting post-internalisation selecting for recycling vs.
receptor degradation. Also assuming a single phosphorylation event prevents
assigning multiple phosphorylation site specific activities to the receptor, this
could in turn affect the quality of simulation fits.
We’ve measured epinephrine-induced GRK-mediated β2AR phosphorylation to
range from 0.7–1.4/min (Tran, Friedman et al. 2004). I assume that
isoproterenol induced β2AR phosphorylation rates will be in the same range
since epinephrine and isoproterenol have comparable efficacies.
We have previously shown that both the plasma membrane and endosomal
fraction of β2AR can undergo dephosphorylation (Iyer, Tran et al. 2006; Tran,
Friedman et al. 2007). Therefore I allow both plasma membrane and cytosolic
dephosphorylation of β2AR in my model (c.f. Footnote of Table 3.1).
5.1.5. PKA Activation Kinetics
Generic PKA activation is modelled here through a series of 10 reactions. The
kinetics of cAMP binding/unbinding to the PKA regulatory subunit and the rate
of release and rebinding of catalytic subunit binding to the regulatory subunit of
PKA in HASMs is assumed to match the rates determined using purified dimer
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of regulatory subunit of PKA I from rabbit skeletal muscle (Doskeland and
Ogreid 1984). These rates will have to be adjusted to match PKA activation in
our cell lines as measured by PKA phosphorylation of the β2AR.
5.1.6. PDE Activation Kinetics
Generic PKA-mediated activation of PDE is modelled here through PKA
phosphorylation of PDE and PDE dephosphorylation. The kinetics of these two
reactions is arbitrarily set to match the cAMP kinetics observed in HEK293 cells
overexpressing the C460W/E583M CNG channel (Xin, Tran et al. 2008). These
rates will have to be adjusted to match cAMP levels in our cell lines in the
presence and absence of PDE inhibitors.
5.1.7. Post-Internalisation Events
I have assumed that there is no PKA or GRK activity post-internalisation so no
new phosphorylation is achieved post-internalisation. Consistent with the rapid
on/off-rates and high Kds of epinephrine or isoproterenol (Mueller, Motulsky et
al. 1988; Devanathan, Yao et al. 2004) I assumed ligand dissociation post
β2AR internalisation to be very rapid. We have previously shown negligible
rates of basal β2AR internalisation (Morrison, Moore et al. 1996).
I allow arrestin-free internalised β2AR to recycle independent of its
phosphorylation status (Tran, Friedman et al. 2007). Currently the precise
mechanisms and pathways of β2AR downregulation are unclear even though
we have shown it to be biphasic (Williams, Barber et al. 2000). Thus to simplify
downregulation reactions in the model I assume that all internalised β2AR
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species can undergo downregulation (t1/2 = 3–4 hours) (Morrison, Moore et al.
1996; Williams, Barber et al. 2000; Liang, Hoang et al. 2008).

5.2. Model Validation
My unified model of GRK-/PKA-/PDE-mediated β2AR regulation has 167 reactions
and 4 initial species. The model has currently been subjected to only
phenomenological validation; extensive quantitative validation is required for this
model as part of future works. Figure 5.6A shows the simulated results of 1 µM
isoproterenol stimulation and figure 5.6B shows cAMP profile in HASMs on
treatment with 1 µM isoproterenol.
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Figure 5.6 1 µM Isoproterenol Stimulation of HASMs
This reaction diagram shows the effect of treatment of HASM with 1 µM isoproterenol. A)
Simulated profiles of: total PKA phosphorylated β2AR (red line); active β2AR (green line); free
cAMP (grey line); PKA-activated PDE (blue line); free catalytic subunit of PKA (black line);
β2ARt0=1µM. B) cAMP in HASMs normalised to maximum levels obtained with 0-300 sec of 1
µM isoproterenol treatment.
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The model shows that receptor activation is near instantaneous and transient. After
a minute of stimulation, active receptor levels reach a steady state of roughly 50 %
of maximal active levels. This is likely a modelling artifact on account of not
considering intermediate receptor activity levels dependent on phosphorylation
status and ignoring arrestin binding. Figure 3.2D clearly shows that 1µM
isoproterenol treatment causes internalisation of close to 40 % of surface β2AR
after minutes. Had I considered arrestin binding in these simulations then the active
β2AR levels would have dropped close to zero within the first five minutes of
treatment with 1µM isoproterenol. This simplification was done to reduce the
complexity of the model to capture first the effects of β2AR-mediated AC activation
on treatment within the first 5 minutes. We know that there is both a high-potency
PKA-mediated desensitisation, and an occupancy-dependent desensitisation
mediated by GRKs (Clark, Knoll et al. 1999). Seeing that we have maximal PKA
phosphorylation of the receptor in a minute, there would be significant PKAmediated desensitisation at the receptor level which is currently being ignored.
Incorporating partial receptor activities based on phosphorylation status should
lower the high steady state receptor activities. The fact that PKA phosphorylation
reaches steady state within 1 minute is congruent with experimental observations
that PKA phosphorylation of receptor reaches near steady state within 1-2 mins on
treatment with 100 nM epinephrine (Tran, Friedman et al. 2004). The simulated
PKA-phosphorylated PDE follows PKA activation. We don’t have an experimental
measure of PKA-phosphorylated PDE in our cell lines. The time course of PKAphosphorylated β2AR and PKA-phosphorylated PDE don’t match on account of the
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different phosphorylation rates used in the model. The rate of PKA phosphorylation
of the β2AR in our HEK293 cells that stably overexpress the β2AR is ~ 83/sec
(Tran, Friedman et al. 2004). The rate of PKA phosphorylation of PDE in our cells
is unknown. I used a rate of ~ 0.015/sec based on our previous models for the
HEK293 cells (Xin, Tran et al. 2008). The rates of PDE phosphorylation will have to
be adjusted to help match the experimental measured cAMP in response to varying
concentrations of isoproterenol. The simulated cAMP profile reaches maximal
levels in ~ 1 minute and the experimentally measured cAMP profile reaches
maximal levels after about 2 minutes. The fact that simulated cAMP levels rise
faster than our experimental measures could be because of one of two reasons (i)
very high AC activity; and (ii) low basal PDE activity. This will have to be fine-tuned
in future simulations. Inspite of this divergence from measured behaviour
simulated cAMP levels at 5 min can be used to study the effects of varying receptor
concentrations to mimic differences between HASMs and HEK293s that stably
over express the β2AR.
5.3. Effect of Varying β2AR Levels
There is ~ 100-fold difference in β2AR levels between stable overexpressions in
HEK293s and endogenous levels in HASMs (Clark and Knoll 2002). I’ve simulated
in Figure 5.7 the effect of variation in receptor levels and of inhibiting GRK-/PKA/PDE-modules when the GRK/arrestin modules are functioning properly.
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Figure 5.7 Effect of [β2AR] Variation in Unified Model Under Different Inhibition
Protocols
This reaction diagram shows the simulated profiles of normalised cAMP in HASMs (β2ARt=0 =
1 µM; green triangle/line) and HEK293s (β2ARt=0 = 100 µM; black square/line). (A) Parameters
as per Table 3.1; (B) PDEt=0 = 0 µM; (C) R2:C2t=0 = 0 µM; (D) GRK Phosphorylation Rate = 0
sec-1.
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As expected from Figure 5.6 basal PDE activity is very low in the model. Therefore
inhibiting PDE by setting initial PDE concentrations to 0 µM does not affect cAMP
at 5 min, hence Figure 5.7A and Figure 5.7B are same. Due to ignoring PKA
effects on the receptor any PKA-mediated desensitisation is through PDE
activation. Figure 5.6 shows that there is a delay in accumulation of catalytic
subunit of PKA and PKA-phosphorylated PDE, because of this there won’t be any
significant effect of inhibiting PKA on the cAMP profile in the first 5 mins poststimulus. Therefore Figure 5.7C will be same as Figure 5.7A. Post ligand treatment
GRK phosphorylation of the receptor is a prerequisite for arrestin binding the
receptor (Krasel, Bunemann et al. 2005). Arrestin binding to the receptor is rapid
and assumed to completely uncouple the receptor from Gαs. Therefore in the
absence of GRK phosphorylation there won’t be any arrestin binding and arrestinmediated desensitisation. Figure 5.7D shows that GRK-/arrestin-mediated β2AR
desensitisation is the dominant mode of β2AR desensitisation in the over
expression system.
5.4. Model Limitations
My model currently ignores effects of PKA mediated β2AR phosphorylation.
Incorporation of variable receptor activity dependent upon phosphorylation status
of the receptor is necessary to capture better the behaviour of the β2AR signaling
machinery at low agonist concentrations. At high agonist concentrations GRKphosphorylation of the β2AR leads to arrestin recruitment and complete uncoupling
of the Gαs from the β2AR thereby reducing the β2AR coupling efficieny for Gs to
zero
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Currently the simulated AC activity is too high and basal PDE activity is too low and
this leads to a faster peak in cAMP production. AC activity and basal PDE activity
can be corrected while validating the model to cAMP profile ± PDE inhibitors.
The model of PDE-mediated β2AR regulation previously developed by our group
(Xin, Tran et al. 2008) used arbitrary concentrations for β2AR levels in HASMs (1
µM) and HEK293s (100 µM). Estimates of local concentrations of membrane bound
proteins are error-prone. One needs an estimate of the plasma membrane volume
and assume point distribution of the protein of interest. My crude estimates (c.f.
Equations 5.1 and 5.2) based on an ideal spherical cell and measured total protein
levels in our cells put the receptor concentration at the ball park range of 0.003 µM
for HASMs and 0.3 µM for HEK293s. I’ll have to validate the model for cAMP
profile ± PDE inhibitors for a range of receptor concentrations and verify if the
simulated properties of overexpression are a function of absolute receptor
concentrations or they are dependent upon the ratio of concentrations.
Given the preponderance of reactions (167!) in this model it is necessary to do a
sensitivity analysis to help prune the model. Stoichiometric analysis will also help in
reducing the number of receptor states in the model.
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6. Conclusions and Future Work
The β2AR is a G-protein coupled receptor that activates smooth muscle relaxation
through both cAMP-dependent and independent pathways (Katsuki and Murad 1977;
Wong and Buckner 1978; Rinard, Rubinfeld et al. 1979; Zhou, Newsholme et al.
1992). Asthma is a chronic disease characterised by; 1) bronchial hyperresponsiveness which leads to increased contraction of the airway smooth muscles; 2)
inflammation; and 3) airway remodelling. Due to its role in smooth muscle relaxation
β-agonists are used in treatment of asthma and COPD (Connors, Dawson et al. 1996;
Celli and MacNee 2004; Donohue 2004). Short acting β-agonists are used as a rescue
agent to bring about immediate airway smooth muscle relaxation to relieve airway
distress. Long acting β-agonists are used in combination with inhaled corticosteroids
on a daily basis as a maintenance therapy to avoid recurrence of asthmatic episodes.
The hallmark of these treatments is that they are only palliative and so they alleviate
the symptom of airway distress and don’t cure the underlying cause of the symptoms.
Due to this, during asthma treatment regimen a patient is repeatedly exposed to the
drugs. Excessive and prolonged use of β-agonists leads to tachyphylaxis – which is
characterised by a tolerance or subsensitivity to the drug leading to the loss of both
broncholdilatory (lung inflation post airway smooth muscle relaxation) and
bronchoprotective (resistance to contraction on inhalation of a bronchioconstrictor)
effects of the drug (Keighley 1966; Van Metre 1969; Davis and Conolly 1980; Sears
2002; Abramson, Walters et al. 2003). For β-agonists, tachyphylaxis occurs due to βdesensitisation and downregulation. In order to understand why clinical tachyphylaxis
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happens in response to β-agonists it becomes necessary to understand agonist
specific activation of the various β2AR desensitisation pathways. These studies are
difficult and extremely time consuming to perform in vivo or in vitro on account of
multiple isoforms and cross-reactions in signalling pathways. Our group’s long-term
goal has been to understand the regulatory mechanisms of the β2AR machinery in
response to both short- and long-acting β-agonists. The ten models that I have
developed and described in the previous chapters represent a significant advance
toward this goal.
In Chapter 3 I have modelled the GRK/Arrestin module of the β2AR regulation as it
pertains to experimental measures of agonist-induced GRK-mediated β2ARphosphorylation, β2AR-dephosphorylation, -trafficking, -desensitisation and resensitisation (Figure 3.1). Table 3.1 lists the parameters used to model and simulate
the consensus GRK pathway in response to various agonists at different
concentrations and durations. The data simulated were from 90+ independent
experiments on our stable overexpressions of human β2AR in HEK 293 cells.
GRK and arrestin isoforms have been frequently targeted for overexpression or
knockdown in different cells types (Ahn, Nelson et al. 2003; Penela, Ribas et al. 2003;
Reiter and Lefkowitz 2006; Violin, Ren et al. 2006; Luo, Busillo et al. 2008). These
proteins also differ in their overall expression levels and localisation (Zhang, Barak et
al. 1997; Komori, Cain et al. 1998). They also undergo post-translational modifications
(Lin, Krueger et al. 1997; Lin, Chen et al. 2002; Penela, Ribas et al. 2003; Shenoy,
Drake et al. 2006). Given that there is wide variability in the level or activity of these
two β2AR regulatory proteins in different cell types I was interested in the effect of this
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variability on the modelling results. In Figure 3.7 I explored the effects of varying GRK
phosphorylation and arrestin binding over a hundred-fold range around rates
mentioned in Table 3.1 and plotted its effects on β2AR phosphorylation,
desensitisation and internalisation over a 0–30 min time course.
The major discoveries from these computational analyses were that steady states of
GRK phosphorylated β2AR were unaffected over hundred-fold variation in GRK
phosphorylation rates (Figure 3.7 A-C) on treatment with saturating concentration (10
µM) of epinephrine. This pointed out a flaw in how most GRK overexpression and
knockdown studies are performed. These usually tend to measure β2AR
phosphorylation at steady state with saturating agonist concentrations; my model
suggests that this would increase the risk of false negative results. A more exacting
measure for the effects of GRK overexpression and knockdown experiments would be
an estimate of the initial rates of GRK-mediated receptor phosphorylation at subsaturating ligand concentrations.
I presented models to test various reaction topologies for GRK-mediated β2AR
regulation. This was done since the possibility of cell surface dephosphorylation of the
GRK phosphorylated β2AR and the recycling of the phosphorylated β2AR has been a
contentious issue (Yu, Lefkowitz et al. 1993; Pippig, Andexinger et al. 1995; Krueger,
Daaka et al. 1997; Iyer, Tran et al. 2006; Kelly 2006). Our group has shown that 1)
blocking internalisation does not prevent β2AR dephosphorylation (Iyer, Tran et al.
2006), and 2) that β2AR dephosphorylation can occur even at undetectable levels of
internalisation (Tran, Friedman et al. 2007). I have determined GRK site β2AR
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dephosphorylation rates at the membrane to be ~0.04/min per method described in
2.1.1.
To investigate the effects of membrane dephosphorylation and phosphorylated
receptor recycling I created six different models (Figure 3.9A-F) that vary different
reactions as described in the footnote of Table 3.1. In Figure 3.9A I modelled our
default reaction topology that allowed for both dephosphorylation of the receptor at the
plasma membrane and phosphorylated receptor recycling. I contrasted this with Figure
3.9F where I modelled a reaction topology that did not allow for both plasma
membrane dephosphorylation and recycling of phosphorylated receptor. This was in
keeping with the prevalent view around early 2000s (Krupnick and Benovic 1998;
Billington and Penn 2003). I showed that under these conditions the system failed to
achieve more than 50% β2AR dephosphorylation which was discordant with our
experimental measurements (Tran, Friedman et al. 2007). Increasing the cytosolic
dephosphorylation rate did not help in rescuing the simulated dephosphorylation
curves. Thus through modeling I was able to show that the prevalent model of early
2000s was not able to explain dephosphorylation measurements done in our lab. I
further explored if random variations in β2AR dephosphorylation and recycling reaction
topologies could explain our experimental results. Through my analyses using these
models I clarified the necessity for β2AR dephosphorylation at the membrane and the
recycling of the GRK phosphorylated receptor.
I further used the models described in Chapter 3 to explore the effects of various
frequencies of agonist treatment since under physiological conditions based on the
target tissue the β2AR “sees” different frequencies and amplitudes of stimuli. Synaptic
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β2AR “sees” high norepinephrine concentrations in a pulsatile fashion (Trendelenburg,
Gaiser et al. 1999; Stjarne 2000) due to the small synaptic volumes, rapid removal and
reuptake of norepinephrine. In contrast to the synaptic stimuli, the bloodstream
concentrations of agonist post epinephrine secretion from the adrenal gland are much
lower but for relatively longer periods. The most exciting results from these
computational analyses were that during pulsatile activation of the β2AR, the signalling
machinery “remembered” prior exposure to an agonist and desensitised much more
strongly on subsequent exposures (Figure 3.11A). This memory of prior stimuli could
be attributed to the accumulation of the GRK phosphorylated β2AR due to slower
dephosphorylation. In subsequent figures (Figure 3.12-3.13) I explored the basis of
this cellular memory and showed (Figure 3.12B) that this memory was robust even
after 2 hours of treatment. Thus this phenomenon could be responsible for the
reduced drug efficacy on repeated use of short acting β-agonists.
After exploring short acting β-agonists in chapter 3 in chapter 4 I developed models of
salmeterol action, a long acting β-agonist used in combination with inhaled
corticosteroids during maintenance therapy of asthma. Briefly, salmeterol action has
been explained by three models. Salmeterol is lipohilic and reversibly incorporates in
the plasma membrane, resulting in a partition of drugs between a membrane and an
aqueous phase (Rhodes, Newton et al. 1992). Due to membrane partitioning of
salmeterol, the membrane can act as a salmeterol reservoir and this forms the basis of
the microkinetic model (MM) (Anderson, Linden et al. 1994) (Figure 4.2). Due to the
high membrane partitioning of salmeterol and its slow rate of release from the
membrane, t1/2 = 25 mins (synthetic membranes) – 3 hours (tracheal strips) (Rhodes,
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Newton et al. 1992; Austin, Barton et al. 2003) it is posited that salmeterol reaches the
receptor by lateral diffusion through the membrane (Anderson, Linden et al. 1994)
since by the time salmeterol traverses the length of the airways to reach the target
bronchii it would have bound to the membrane on account of its lipophilicity.
Per the exosite model (EM) (Figure 4.4) the saligenin head of salmeterol (Figure 1.2)
and the hydrophobic phenylalkoxyalkyl side chain binds the β2AR at two spatially
distinct sites. The site of saligenin head binding is identified as the active site and the
site of hydrophobic phenylalkoxyalkyl side chain binding is called an exosite. In the
exosite model tethering of the phenylalkoxyalkyl chain to the exosite is quasiirreversible while the binding of the saligenin head to the active site is rapidly
reversible. This model also allows agonist or antagonist binding to the active site when
the exosite is occupied by salmeterol’s hydrophobic tail (Figure 6.1). To allow the
flipping in and out of the saligenin head from the active site, the exosite has been
posited to be in the central core of the β2AR (Jack 1991). Both site directed
mutagenesis studies involving replacement of β2AR central domains with β1AR
(Green, Spasoff et al. 1996; Isogaya, Yamagiwa et al. 1998) and photoaffinity labeling
with [125I]iodoazido-salmeterol (Rong, Arbabian et al. 1999) lend credence to the idea
that the exosite is further into the transmembrane domains toward the cytosol than the
active site.
The rebinding model posits that a high local concentration of salmeterol is
maintained on account of rapid rebinding (Szczuka, Wennerberg et al. 2009). This
model wouldn’t be able to explain the reassertion phenomenon when a competing
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ligand is present without invoking another mechanism to retain salmeterol in the
vicinity of the receptor.
Given the importance of salmeterol in treating asthma and COPD I developed
phenomenological models to describe the effects of membrane retention of salmeterol,
exosite binding or a composite of the two (combined model - CM). I then coupled
these models to an adaptation of the GRK-mediated β2AR regulation model
developed in Chapter 3 and then tested them to see if properties of salmeterol long
action and reassertion still held true. Using these models I show (Figure 4.10A) that
none of the three currently accepted models can sufficiently explain the long action of
salmeterol or significantly reduced β2AR internalisation (Figure 4.10B) on treatment
with saturating concentrations of salmeterol. It becomes necessary to invoke
decreased arrestin affinity for salmeterol bound β2AR complex in order to simulate
experimentally measured salmeterol-induced β2AR internalisation (Vayttaden,
Friedman et al. 2010) and to rescue loss of long action to explain the long action of
salmeterol (Figure 4.10C).
In Chapter 5 I described an alpha version of the unified model of GRK-/PKA-/PDEmediated β2AR regulation. This model explores the effect of variation in receptor
number (Figure 5.6). Once validated, this model will be an important tool to study the
effects of various beta agonists on GRK- and PKA-mediated β2AR regulation in
HASMs where the low receptor number makes phosphorylation experiments difficult.
This model can eventually be used to discover the relative contribution of PKA, GRK,
PDE, arrestin and internalisation to the total β2AR desensitisation on treatment with
various beta agonists. This information in turn would be valuable in deciding what
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desensitisation modules are best targeted pharmacologically for most effective use of
individual beta agonists.
A well tested comprehensive model of β2AR regulation would aid in: (i) understanding
tissue specific mechanistic differences in β2AR response; (ii) in-silico estimation of
tachyphylaxis associated with prolonged use of different β2AR agonists; (iii)
hypothesis testing and in-silico prediction of experimental results. Some of the future
work planned to understand β2AR regulation is described below.
6.1. Salmeterol Models
The salmeterol models presented in Chapter 4 deals only with GRK-mediated
β2AR regulation. Since the GRK-mediated β2AR phosphorylation profile at
saturating salmeterol concentrations are similar to that obtained with about 50 nM
isoproterenol, it is expected that PKA- and PDE-modules would be significant
players in β2AR regulation. I need to expand the combined model (Model 9)
representing salmeterol exosite, microkinetic and rebinding effects to include PKAand PDE-mediated β2AR regulation.

175

Figure 6.1 Model of Salmeterol Bitopic Action.
Grey cylinders = β2AR; white triangle = empty active site; white circle = empty exosite; green
triangle = active site occupied by isoproterenol; red triangle = active site occupied by
salmeterol; red circle = exosite occupied by salmeterol. A = naïve β2AR; B = salmeterol bound
to an exosite on the β2AR; C = salmeterol bound to the active site on the β2AR; D =
salmeterol bound to both the active- and exo-site on the β2AR; E = isoproterenol bound to the
active site on the β2AR; F = β2AR having isoproterenol bound to the active site and salmeterol
to the exosite.
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Salmeterol is a bitopic ligand since it binds the β2AR both at an active site and an
exosite (Johnson, Butchers et al. 1993; Green, Spasoff et al. 1996; Isogaya,
Yamagiwa et al. 1998; Rong, Arbabian et al. 1999). In Figure 6.1 I have shown the
minimum number of β2AR states to accommodate isoproterenol and salmeterol
binding per the exosite model. In the interest of simplification, in the models
simulated in Chapter 4 I’ve ignored a β2AR state that has salmeterol bound only to
the active site with an empty exosite (state D in Figure 6.1) since I expect all
exosite to be occupied by salmeterol when β2AR is treated with saturating
concentrations of salmeterol for long periods of time. The number of β2AR states
now increases exponentially while allowing for GRK- and PKA-mediated β2AR
phosphorylation, arrestin binding and internalisation of the β2AR. Thus a unified
GRK-/PKA-/PDE-mediated β2AR regulation model that simulates salmeterol
exosite, microkinetic and rebinding effects is not easily tractable on account of an
exponential increase in receptor species. Such a model is best attempted after the
unified GRK-/PKA-/PDE-mediated β2AR regulation model for monotopic ligands as
described in Chapter 5 is well validated and constrained. Since salmeterol
treatment is for longer durations and it brings about negligible β2AR internalisation
I’d have to incorporate additional reactions to capture the β2AR degradation
kinetics.
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6.2. GRK-/PKA-/PDE-Mediated Regulation
The model of GRK-/PKA-/PDE-mediated regulation of β2AR signalling described in
Chapter 5 has 167 reactions. There are a few quality control measures that need to
be taken. I need to do a stoichiometric state analysis to calculate mass
conservation. Since my model is implemented in COPASI I’ll be using the
Householder reduction method (Householder 1958; Vallabhajosyula, Chickarmane
et al. 2006). The model also needs to be subjected to sensitivity analysis similar to
analysis done in Figures 2.5-6 and for cAMP profile. The results of the
stoichiometric state analysis and sensitivity analysis will help determine if reactions
need to be pruned.
Currently I have only done a rudimentary phenomenological validation of the
model. I need to extend the model validation to a more exhaustive set of time
course profiles that cover PKA- and GRK-mediated β2AR phosphorylation, cAMP
profile (± PDE inhibitors ± propranolol), β2AR trafficking (internalisation and
recycling), and β2AR activity (desensitisation and resensitisation) for different
monotopic agonists and concentrations. Once the model has been well constrained
through experimental validation, stoichiometric state analysis and sensitivity
analysis I will use the model to predict the percent contribution of each regulatory
module to total β2AR desensitisation.
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6.3. β2AR and Pro-Inflammatory Signalling Pathway Crosstalk
Currently little is known about how salmeterol-mediated β2AR desensitisation
pathways are altered with co-treatment of corticosteroids or under conditions of
inflammation. The effect of corticosteroid and pro-inflammation mediated signalling
on agonist induced β2AR desensitisation is important given that LABAs such as
salmeterol are used clinically in asthmatic patients as a chronic medication in
combination with inhaled corticosteroids. Recently, the Penn group has published
data regarding the effect of PKA on the HASM transcriptome. They determined
transcriptional changes using mRNA array technology following the introduction of
a genetic inhibitor of PKA (GFP-PKI) under pro-inflammatory conditions and in the
presence or absence of corticosteroids. A major finding of this study was that PKA
is a critical modulator of the transcriptional changes induced by pro-inflammatory
cytokines, particularly with regard to their promitogenic effects (Misior, Deshpande
et al. 2009). They have also shown that corticosteroids can suppress β agonistinduced PKA activity thus inhibiting the mitogenic effects of cytokines (Misior, Yan
et al. 2008) and that the anti-mitogenic effects of β-agonists (including salmeterol)
are mediated by PKA (Yan, Deshpande et al. 2011). Modelling the crosstalk
between salmeterol-mediated β2AR regulatory pathways and pro-inflammatory
signalling pathways will have to be complemented with experiments. Salmeterolmediated β2AR desensitisation will have to be measured in the presence of
corticosteroid like fluticasone propionate in both naïve cells as well as under
cytokine-mediated inflammatory conditions, to mimic signaling in the asthmatic
airway. The application of these results to my quantitative model will provide a
179

more complete picture of how β2AR signaling functions in disease states and an
improved understanding of β agonist mediated crosstalk with pro-inflammatory
pathways.
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